NO135315B - - Google Patents
Download PDFInfo
- Publication number
- NO135315B NO135315B NO7121A NO2171A NO135315B NO 135315 B NO135315 B NO 135315B NO 7121 A NO7121 A NO 7121A NO 2171 A NO2171 A NO 2171A NO 135315 B NO135315 B NO 135315B
- Authority
- NO
- Norway
- Prior art keywords
- formula
- tetrahydro
- compound
- rac
- hydrochloride
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 230000008569 process Effects 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 98
- -1 di-substituted amino group Chemical group 0.000 claims description 39
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 22
- 125000003277 amino group Chemical group 0.000 claims description 21
- 239000012458 free base Substances 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000002378 acidificating effect Effects 0.000 claims description 13
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000007858 starting material Substances 0.000 claims description 8
- OSZMNJRKIPAVOS-UHFFFAOYSA-N 4-phenyl-1,2,3,4-tetrahydroisoquinoline Chemical class C1NCC2=CC=CC=C2C1C1=CC=CC=C1 OSZMNJRKIPAVOS-UHFFFAOYSA-N 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 238000005661 deetherification reaction Methods 0.000 claims description 7
- ZJDCGVDEEHWEIG-UHFFFAOYSA-N diclofensine Chemical compound C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-UHFFFAOYSA-N 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- SGTJISQIEGVZGI-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol Chemical compound C12=CC=C(O)C=C2CN(C)CC1C1=CC=C(Cl)C(Cl)=C1 SGTJISQIEGVZGI-UHFFFAOYSA-N 0.000 claims description 3
- DFMPEQSDFDFZAQ-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol Chemical compound C12=CC=C(O)C=C2CN(C)CC1C1=CC=C(Cl)C=C1 DFMPEQSDFDFZAQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004423 acyloxy group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 116
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 99
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 67
- 238000001953 recrystallisation Methods 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000000243 solution Substances 0.000 description 50
- 239000002585 base Substances 0.000 description 46
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 46
- 238000001704 evaporation Methods 0.000 description 42
- 230000008020 evaporation Effects 0.000 description 42
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 38
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 32
- 230000020477 pH reduction Effects 0.000 description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
- 238000002425 crystallisation Methods 0.000 description 27
- 230000008025 crystallization Effects 0.000 description 27
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- 235000011167 hydrochloric acid Nutrition 0.000 description 17
- 235000011121 sodium hydroxide Nutrition 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 15
- 238000010992 reflux Methods 0.000 description 14
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 13
- 239000012279 sodium borohydride Substances 0.000 description 13
- 229910000033 sodium borohydride Inorganic materials 0.000 description 13
- ZJDCGVDEEHWEIG-HNNXBMFYSA-N (4s)-4-(3,4-dichlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinoline Chemical compound C1([C@H]2C3=CC=C(C=C3CN(C)C2)OC)=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-HNNXBMFYSA-N 0.000 description 12
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 12
- 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical compound COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 10
- 239000007868 Raney catalyst Substances 0.000 description 10
- 229910000564 Raney nickel Inorganic materials 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000005245 sintering Methods 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 239000008098 formaldehyde solution Substances 0.000 description 9
- 239000012280 lithium aluminium hydride Substances 0.000 description 9
- 239000000741 silica gel Substances 0.000 description 9
- 229910002027 silica gel Inorganic materials 0.000 description 9
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N hydroxymethyl benzene Natural products OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- RTJYPROKPMILEK-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 RTJYPROKPMILEK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- ZJDCGVDEEHWEIG-OAHLLOKOSA-N (4r)-4-(3,4-dichlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinoline Chemical compound C1([C@@H]2C3=CC=C(C=C3CN(C)C2)OC)=CC=C(Cl)C(Cl)=C1 ZJDCGVDEEHWEIG-OAHLLOKOSA-N 0.000 description 5
- 230000001430 anti-depressive effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 4
- PEHOXCSPLOXNOK-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinoline;hydron;chloride Chemical compound Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 PEHOXCSPLOXNOK-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003054 catalyst Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 4
- 229910003446 platinum oxide Inorganic materials 0.000 description 4
- 229920000137 polyphosphoric acid Polymers 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 125000002774 3,4-dimethoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 3
- NURFKPOSAJCQTH-UHFFFAOYSA-N 4-(4-chlorophenyl)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1=2C=C(OC)C(OC)=CC=2CN(C)CC1C1=CC=C(Cl)C=C1 NURFKPOSAJCQTH-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229940005513 antidepressants Drugs 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 150000002537 isoquinolines Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- AKIKYWSEBGSZBD-UHFFFAOYSA-N 2-methyl-1h-isoquinoline Chemical compound C1=CC=C2C=CN(C)CC2=C1 AKIKYWSEBGSZBD-UHFFFAOYSA-N 0.000 description 2
- PBYMYAJONQZORL-UHFFFAOYSA-N 2-methylisoquinoline Natural products C1=CC=C2C(C)=NC=CC2=C1 PBYMYAJONQZORL-UHFFFAOYSA-N 0.000 description 2
- LCJIQLVGZBCSAV-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-5-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=2C(OC)=CC=CC=2C(C)NCC1C1=CC=C(Cl)C(Cl)=C1 LCJIQLVGZBCSAV-UHFFFAOYSA-N 0.000 description 2
- HRLGLJUBRANEGZ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-7-methoxy-1,2-dimethyl-3,4-dihydro-1h-isoquinoline Chemical compound C1N(C)C(C)C2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 HRLGLJUBRANEGZ-UHFFFAOYSA-N 0.000 description 2
- SQTQPRPKDZDAGV-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-7-methoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NC(C)C2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 SQTQPRPKDZDAGV-UHFFFAOYSA-N 0.000 description 2
- UMKZHXUGFJDIQU-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-7-methoxy-2-propan-2-yl-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1N(C(C)C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 UMKZHXUGFJDIQU-UHFFFAOYSA-N 0.000 description 2
- SKKMBBLWDNSRLL-UHFFFAOYSA-N 4-(3-chlorophenyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCC2=CC(OC)=CC=C2C1C1=CC=CC(Cl)=C1 SKKMBBLWDNSRLL-UHFFFAOYSA-N 0.000 description 2
- CYWOYWVGDXGPCG-UHFFFAOYSA-N 4-(3-chlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=CC(Cl)=C1 CYWOYWVGDXGPCG-UHFFFAOYSA-N 0.000 description 2
- VGZDOZROHWTHQP-UHFFFAOYSA-N 4-(4-chlorophenyl)-7-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C=C1 VGZDOZROHWTHQP-UHFFFAOYSA-N 0.000 description 2
- LOVFKDKOAPQDNK-UHFFFAOYSA-N 4-(4-chlorophenyl)-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(Cl)C=C1 LOVFKDKOAPQDNK-UHFFFAOYSA-N 0.000 description 2
- JWQCNUWRYVLUPL-UHFFFAOYSA-N 4-(7-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-4-yl)aniline;dihydrochloride Chemical compound Cl.Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C(N)C=C1 JWQCNUWRYVLUPL-UHFFFAOYSA-N 0.000 description 2
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 2
- LCIZALBRTMPJEE-UHFFFAOYSA-N 7-methoxy-2-methyl-4-(3-nitrophenyl)-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=CC([N+]([O-])=O)=C1 LCIZALBRTMPJEE-UHFFFAOYSA-N 0.000 description 2
- VKWRGVQUOMQCMH-UHFFFAOYSA-N 7-methoxy-2-methyl-4-(4-nitrophenyl)-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C1N(C)CC2=CC(OC)=CC=C2C1C1=CC=C([N+]([O-])=O)C=C1 VKWRGVQUOMQCMH-UHFFFAOYSA-N 0.000 description 2
- PXZLUIQRFAUJRK-UHFFFAOYSA-N 7-methoxy-4-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCC2=CC(OC)=CC=C2C1C1=CC=C([N+]([O-])=O)C=C1 PXZLUIQRFAUJRK-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010015995 Eyelid ptosis Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- WVYBKVIVGZLWOS-UHFFFAOYSA-N benzyloxidanium;chloride Chemical compound Cl.OCC1=CC=CC=C1 WVYBKVIVGZLWOS-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 2
- JMSRBKPMLUGHCR-UHFFFAOYSA-N bromohydrin Chemical compound BrC[C]1CO1 JMSRBKPMLUGHCR-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- JVTZFYYHCGSXJV-UHFFFAOYSA-N isovanillin Chemical compound COC1=CC=C(C=O)C=C1O JVTZFYYHCGSXJV-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- XOAGCJPTMIRCMN-KCJUWKMLSA-N (2S,3S)-2-benzyl-2,3-dihydroxybutanedioic acid Chemical compound C(C1=CC=CC=C1)[C@](C(=O)O)(O)[C@H](O)C(=O)O XOAGCJPTMIRCMN-KCJUWKMLSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BAYUSCHCCGXLAY-UHFFFAOYSA-N 1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(C)=O)=C1 BAYUSCHCCGXLAY-UHFFFAOYSA-N 0.000 description 1
- ARKIFHPFTHVKDT-UHFFFAOYSA-N 1-(3-nitrophenyl)ethanone Chemical compound CC(=O)C1=CC=CC([N+]([O-])=O)=C1 ARKIFHPFTHVKDT-UHFFFAOYSA-N 0.000 description 1
- JJJJEMMIVKADHL-UHFFFAOYSA-N 1-methoxy-2-methyl-1H-isoquinoline Chemical compound COC1N(C=CC2=CC=CC=C12)C JJJJEMMIVKADHL-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 1
- LOAWQYGQFGUNMF-UHFFFAOYSA-N 2-methyl-4-(4-nitrophenyl)-3,4-dihydro-1h-isoquinolin-7-ol;hydrochloride Chemical compound Cl.C12=CC=C(O)C=C2CN(C)CC1C1=CC=C([N+]([O-])=O)C=C1 LOAWQYGQFGUNMF-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- KQVPFXMIJVSCDI-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinolin-7-ol Chemical compound C1NCC2=CC(O)=CC=C2C1C1=CC=C(Cl)C(Cl)=C1 KQVPFXMIJVSCDI-UHFFFAOYSA-N 0.000 description 1
- ZNKKUAMMUNNQQL-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-ethyl-3,4-dihydro-1h-isoquinolin-7-ol;hydrochloride Chemical compound Cl.C12=CC=C(O)C=C2CN(CC)CC1C1=CC=C(Cl)C(Cl)=C1 ZNKKUAMMUNNQQL-UHFFFAOYSA-N 0.000 description 1
- LECBDTBWASOEBH-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-ethyl-7-methoxy-3,4-dihydro-1h-isoquinoline;hydrochloride Chemical compound Cl.C12=CC=C(OC)C=C2CN(CC)CC1C1=CC=C(Cl)C(Cl)=C1 LECBDTBWASOEBH-UHFFFAOYSA-N 0.000 description 1
- RJZVEXSVSOIBOT-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol;hydrobromide Chemical compound Br.C12=CC=C(O)C=C2CN(C)CC1C1=CC=C(Cl)C(Cl)=C1 RJZVEXSVSOIBOT-UHFFFAOYSA-N 0.000 description 1
- UERXQCDUTUBSCA-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-propan-2-yl-3,4-dihydro-1h-isoquinolin-7-ol Chemical compound C12=CC=C(O)C=C2CN(C(C)C)CC1C1=CC=C(Cl)C(Cl)=C1 UERXQCDUTUBSCA-UHFFFAOYSA-N 0.000 description 1
- RSFKORQDYRAHEO-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-5-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C(OC)=CC=CC=2CNCC1C1=CC=C(Cl)C(Cl)=C1 RSFKORQDYRAHEO-UHFFFAOYSA-N 0.000 description 1
- JFNKCWMKGBPOBI-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C=C(OC)C(OC)=CC=2CNCC1C1=CC=C(Cl)C(Cl)=C1 JFNKCWMKGBPOBI-UHFFFAOYSA-N 0.000 description 1
- PAILVDNZBXJXED-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol;hydrochloride Chemical compound Cl.C1NCC=2C=C(O)C(OC)=CC=2C1C1=CC=C(Cl)C(Cl)=C1 PAILVDNZBXJXED-UHFFFAOYSA-N 0.000 description 1
- RWLFNZUMGWPYOC-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol;hydrochloride Chemical compound Cl.C12=CC=C(O)C=C2CN(C)CC1C1=CC=CC(Cl)=C1 RWLFNZUMGWPYOC-UHFFFAOYSA-N 0.000 description 1
- IMOPVTDNINKIMD-UHFFFAOYSA-N 4-(3-chlorophenyl)-5-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C(OC)=CC=CC=2CNCC1C1=CC=CC(Cl)=C1 IMOPVTDNINKIMD-UHFFFAOYSA-N 0.000 description 1
- HYGXXHDYSLTOIO-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol;hydrobromide Chemical compound Br.C12=CC=C(O)C=C2CN(C)CC1C1=CC=C(Cl)C=C1 HYGXXHDYSLTOIO-UHFFFAOYSA-N 0.000 description 1
- ALKMPPGKOWTEAZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-5-methoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C(OC)=CC=CC=2CNCC1C1=CC=C(Cl)C=C1 ALKMPPGKOWTEAZ-UHFFFAOYSA-N 0.000 description 1
- PTQLNBAECCFSLK-UHFFFAOYSA-N 4-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C=C(OC)C(OC)=CC=2CNCC1C1=CC=C(Cl)C=C1 PTQLNBAECCFSLK-UHFFFAOYSA-N 0.000 description 1
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 1
- BUERIMSSPLXKSU-UHFFFAOYSA-N 5-methoxy-4-(4-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1=2C(OC)=CC=CC=2CNCC1C1=CC=C([N+]([O-])=O)C=C1 BUERIMSSPLXKSU-UHFFFAOYSA-N 0.000 description 1
- BPSLFSXCUJYFIR-UHFFFAOYSA-N 7-methoxy-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=CC(OC)=CC=C21 BPSLFSXCUJYFIR-UHFFFAOYSA-N 0.000 description 1
- RLHUUYYENAZXKO-UHFFFAOYSA-N 7-methoxy-4-(3-nitrophenyl)-1,2,3,4-tetrahydroisoquinoline;hydrochloride Chemical compound Cl.C1NCC2=CC(OC)=CC=C2C1C1=CC=CC([N+]([O-])=O)=C1 RLHUUYYENAZXKO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DQMGNSDRSWHWRW-UHFFFAOYSA-N Cl.OC1(C(CN2CCC3=C(C2C1)C=C(C(=C3)OC)OC)CC(C)C)CC Chemical compound Cl.OC1(C(CN2CCC3=C(C2C1)C=C(C(=C3)OC)OC)CC(C)C)CC DQMGNSDRSWHWRW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- OVHDZBAFUMEXCX-UHFFFAOYSA-N benzyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCC1=CC=CC=C1 OVHDZBAFUMEXCX-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- QSKWJTXWJJOJFP-UHFFFAOYSA-N chloroform;ethoxyethane Chemical compound ClC(Cl)Cl.CCOCC QSKWJTXWJJOJFP-UHFFFAOYSA-N 0.000 description 1
- YALYLPKSKBQFJP-UHFFFAOYSA-N chloroform;n-ethylethanamine Chemical compound ClC(Cl)Cl.CCNCC YALYLPKSKBQFJP-UHFFFAOYSA-N 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- IYRMNDOLPONSCJ-UHFFFAOYSA-N isoquinolin-2-ium;chloride Chemical compound Cl.C1=NC=CC2=CC=CC=C21 IYRMNDOLPONSCJ-UHFFFAOYSA-N 0.000 description 1
- WCRKBMABEPCYII-UHFFFAOYSA-N isoquinolin-7-ol Chemical class C1=CN=CC2=CC(O)=CC=C21 WCRKBMABEPCYII-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Analogifremgangsmåte til fremstilling av terapeutisk aktive tetrahydro-isokinolinderivater.Analogy process for the preparation of therapeutically active tetrahydro-isoquinoline derivatives.
Description
Nærværende oppfinnelse vedrorer fremgangsmåte til fremstilling av isokinolin-derivater. Spesielt vedrorer den fremgangsmåte til fremstilling av 1,2,3,4-tetrahydro-4-fenylisokinolin-derivater med den generelle formel, The present invention relates to a process for the production of isoquinoline derivatives. In particular, it relates to the process for the preparation of 1,2,3,4-tetrahydro-4-phenylisoquinoline derivatives with the general formula,
hvor R betyr hydroksy eller lavere alkoksy, where R means hydroxy or lower alkoxy,
R, hydrogen, hydroksy eller lavere alkoksy, R, hydrogen, hydroxy or lower alkoxy,
R^ hydrogen eller lavere alkyl, R^ hydrogen or lower alkyl,
R^ lavere alkyl eller fenyl-lavere alkyl, R^ lower alkyl or phenyl-lower alkyl,
R^ halogen, nitro eller eventuelt med lavere alkyl mono- eller disubstituert amino og R^ halogen, nitro or optionally with lower alkyl mono- or disubstituted amino and
n tallet 1 eller 2, n the number 1 or 2,
såvel som syreaddisjonssalter av disse forbindelser. as well as acid addition salts of these compounds.
Uttrykket "lavere alkyl" betegner en rettkjedet eller forgrenet mettet hydrokarbonrest med 1-4 karbonatomer, som f.eks. metyl, etyl, isopropyl o.l. Uttrykket "fenyl-lavere alkyl" betegner rettkjedete eller forgrenete mettede hydrokarbon-rester med 1-4 karbonatomer, som er substituert med en fenylrest, som f.eks. benzyl, 2-fenyletyl o.l. Med "lavere alkoksy" forstås rettkjedete eller forgrenete lavere alkylrester, som er bundet via et oksygenatom, som metoksy, etoksy, iso-propoksy osv. Uttrykket "acyloksy" betegner en acylrest, som er bundet via. et oksygenatom. Foretrukket er lavere alkanoyl-rester. Uttrykket "lavere alkanoyl" betegner resten av en alifatisk mettet karboksylsyre med hoyst 4 karbonatomer, som acetyl, propionyl o.l. Såfremt ikke annet er angitt, forstås med "halogen" de fire halogenene fluor, klor, brom og jod. Blant forbindelser med formel I foretrekkes de som i 7-stilling i isokinolin-skjelettet har en metoksy- eller en hydroksy-substituent. I en spesielt foretrukket utforelsesform oppviser forbindelser med formel I bare en av de nevnte substituentene i 7-stilling, dvs. at substituenten R^ har betydningen hydrogen; The term "lower alkyl" denotes a straight-chain or branched saturated hydrocarbon residue with 1-4 carbon atoms, such as e.g. methyl, ethyl, isopropyl, etc. The term "phenyl-lower alkyl" denotes straight-chain or branched saturated hydrocarbon residues with 1-4 carbon atoms, which are substituted with a phenyl residue, such as e.g. benzyl, 2-phenylethyl, etc. By "lower alkoxy" is meant straight-chain or branched lower alkyl residues, which are attached via an oxygen atom, such as methoxy, ethoxy, iso-propoxy, etc. The term "acyloxy" denotes an acyl residue, which is attached via. an oxygen atom. Lower alkanoyl residues are preferred. The term "lower alkanoyl" denotes the residue of an aliphatic saturated carboxylic acid with at most 4 carbon atoms, such as acetyl, propionyl and the like. Unless otherwise stated, "halogen" means the four halogens fluorine, chlorine, bromine and iodine. Among compounds of formula I, those which have a methoxy or a hydroxy substituent in the 7-position of the isoquinoline skeleton are preferred. In a particularly preferred embodiment, compounds of formula I exhibit only one of the aforementioned substituents in the 7-position, i.e. that the substituent R 1 has the meaning hydrogen;
Blant forbindelsene med formel I, er de foretrukket hvor begge orto-stiIlinger i fenylresten, som sitter i isokinolin-skjelettets 4-stilling, er usubstituerte, dvs. de forbindelser hvor den nevnte fenylresten oppviser den eller de under R^ angitte substituenter i para- og/eller i meta-stilling. Resten R^ er fortrinnsvis halogen, og da spesielt klor. Spesielt foretrukne er de forbindelser med formel I som i isokinolin-skjelettets 4-stilling oppviser en 4-klorfenyl- eller en 3,4-diklorfenylrest, dvs. forbindelser hvorved n = 1 og R betyr klor i para-stilling hhv. n = 2 og R betyr klor i para- og meta-stilling. Among the compounds of formula I, those are preferred where both ortho-positions in the phenyl residue, which sits in the 4-position of the isoquinoline skeleton, are unsubstituted, i.e. the compounds where the said phenyl residue exhibits the substituent(s) indicated under R^ in the para- and/or in meta position. The residue R^ is preferably halogen, and then especially chlorine. Particularly preferred are the compounds of formula I which in the 4-position of the isoquinoline skeleton have a 4-chlorophenyl or a 3,4-dichlorophenyl residue, i.e. compounds where n = 1 and R means chlorine in the para-position or n = 2 and R means chlorine in the para and meta position.
Dessuten foretrekkes innen rammen av nærværende oppfinnelse de forbindelser med formel I hvor R_ betegner en substituent i 2-stilling i isokinolin-strukturen, hvorved R^ betyr en metyl-eller etylgruppe. Moreover, within the scope of the present invention, the compounds of formula I are preferred where R 1 denotes a substituent in the 2-position in the isoquinoline structure, whereby R 1 denotes a methyl or ethyl group.
Likeledes foretrekkes slike forbindelser med formel I, hvorved 1-stillingen i isokinolin-strukturen er usubstituert, dvs. slike hvor R~ betyr hydrogen. Likewise, such compounds of formula I are preferred, whereby the 1-position in the isoquinoline structure is unsubstituted, i.e. those where R~ means hydrogen.
Innen rammen av nærværende oppfinnelse er Within the scope of the present invention is
representative forbindelser foretrukket blant folgende forbindelser med formel I: 4-(4-klorfenyl)-l,2,3,4-tetrahydro-2-metyl-7-isokinolinol, 4_(4-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyl-isokinolin, 4-(3,4-diklorfenyl)-l,2,3,4-tetrahydro-2-metyl-7-isokinolinol og 4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin. representative compounds preferred among the following compounds of formula I: 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol, 4_(4-chlorophenyl)-1,2,3,4 -tetrahydro-7-methoxy-2-methyl-isoquinoline, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol and 4-(3,4-dichlorophenyl) -1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline.
1,2,3,4-tetrahydro-4-fenyl-isokinoliirderivatene, som erholdes ifolge oppfinnelsen, atskiller seg på karakteristisk måte fra de i Chem.Abstr. 52, 7319h, åpenbarte 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivatene ved.et tertiært nitrogenatom samt ved en eller to halogenatomer, henholdsvis nitro- eller eventuelt alkylsubstituerte aminogrupper i.fenylringen. De i det norske patent nr. 121.721 åpenbarte 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivatene atskiller seg fra de foreliggende ved en eventuelt substituert aminogruppe i 8-stilling. 1,2,3,4-tetrahydro-4-fenyl-isokinolinderivatene med formelen I som erholdes ifolge oppfinnelsen og deres salter er de kjente forbindelser overlegne med hensynt til antidepressiv virkning og utgjor derfor en ikke-nærliggende berikelse på legemiddel-området. The 1,2,3,4-tetrahydro-4-phenyl-isoquinoline derivatives, which are obtained according to the invention, differ in a characteristic way from those in Chem.Abstr. 52, 7319h, revealed the 1,2,3,4-tetrahydro-4-phenyl-isoquinoline derivatives by a tertiary nitrogen atom as well as by one or two halogen atoms, respectively nitro- or optionally alkyl-substituted amino groups in the phenyl ring. The 1,2,3,4-tetrahydro-4-phenyl-isoquinoline derivatives disclosed in Norwegian patent no. 121,721 differ from the present ones by an optionally substituted amino group in the 8-position. The 1,2,3,4-tetrahydro-4-phenyl-isoquinoline derivatives of the formula I which are obtained according to the invention and their salts are superior to the known compounds with regard to antidepressant action and therefore constitute a non-adjacent enrichment in the pharmaceutical area.
Forbindelser med formel I og deres syreaddisjonssalter kan ifolge oppfinnelsen fremstilles ved at man According to the invention, compounds of formula I and their acid addition salts can be prepared by
a) cykliserer en forbindelse med den generelle formel a) cyclizes a compound of the general formula
hvor R, R1, R2, R3, R4 og n har de i formel I where R, R1, R2, R3, R4 and n have those in formula I
angitte betydninger, og X står for hydroksy, acyloksy eller halogen, given meanings, and X stands for hydroxy, acyloxy or halogen,
eller or
b) for fremstilling av en forbindelse med formelen I, hvor R^ betyr halogen, nitro eller en med lavere alkyl disubstituert b) for the preparation of a compound of the formula I, where R 1 means halogen, nitro or a lower alkyl disubstituted
aminogruppe, lavere-alkylérer. eller fenyl-lavere-alkylerer en forbindelse med den generelle formel amino group, lower-alkyler. or phenyl-lower-alkylates a compound of the general formula
hvor R, R^ , R2 og n har de i formel I angitte betydninger, og R^ betyr halogen, nitro eller en med where R, R^, R2 and n have the meanings given in formula I, and R^ means halogen, nitro or one with
lavere alkyl disubstituert aminogruppe, lower alkyl disubstituted amino group,
eller or
c) for fremstilling av en forbindelse med formelen I, hvor R^ står for halogen eller en med lavere alkyl disubstituert aminogruppe, og hvor R og R^ må være forskjellig fra hydroksy og R^ fra benzyl, reduserer en forbindelse med den generelle formel c) for the preparation of a compound of the formula I, where R^ stands for halogen or a lower alkyl disubstituted amino group, and where R and R^ must be different from hydroxy and R^ from benzyl, reduces a compound of the general formula
hvor R, R^, R^, R^ og n har de i formel I angitte betydninger, R^ står for halogen eller en med lavere alkyl disubstituert aminogruppe, og R og R^ må være forskjellig fra hydroksy og R^ fra benzyl, under sure betingelser, eller reduserer en forbindelse med.. den generelle formel where R, R^, R^, R^ and n have the meanings given in formula I, R^ stands for halogen or a lower alkyl disubstituted amino group, and R and R^ must be different from hydroxy and R^ from benzyl, under acidic conditions, or reduces a compound with.. the general formula
hvor R, R1, R2, R3, R4 og n har de i formel IV where R, R1, R2, R3, R4 and n have those in formula IV
angitte betydninger, stated meanings,
eller or
d) for fremstilling av en forbindelse med formel I, hvor R^ står for halogen eller eventuelt med lavere alkyl, mono-eller disubstituert aminogruppe, og R^ er forskjellig fra benzyl, reduserer en forbindelse med den generelle formel d) for the preparation of a compound of formula I, where R^ stands for halogen or optionally with a lower alkyl, mono- or disubstituted amino group, and R^ is different from benzyl, reduces a compound of the general formula
hvor R, R^, R2, R^, R^ og n har de under formel I where R, R^, R2, R^, R^ and n have those under formula I
angitte betydninger og R3 er forskjellig fra benzyl, eller given meanings and R 3 is different from benzyl, or
e) for fremstilling av en forbindelse med formel I, hvor R og/eller R^ betyr hydroksy, underkaster en forbindelse med e) for the preparation of a compound of formula I, where R and/or R^ means hydroxy, subject a compound with
den generelle formel the general formula
hvor R2, R3, R4 og n har de i formel I angitte where R2, R3, R4 and n have those in formula I indicated
betydninger, og R og/eller R.^ betyr lavere alkoksy, en sur eteravspaltning, eller meanings, and R and/or R.sub.3 means lower alkoxy, an acidic ether cleavage, or
f) for fremstilling av en forbindelse med formel I hvor R^ betyr amino og R er forskjellig fra benzyl, reduserer en f) for the preparation of a compound of formula I where R 1 means amino and R is different from benzyl, reduces a
forbindelse med formelen connection with the formula
hvor R, R^, R2, R^°Q n har de i formel I angitte where R, R^, R2, R^°Q n have those in formula I indicated
betydninger, og R^ er forskjellig fra benzyl, meanings, and R 1 is different from benzyl,
eller or
g) for fremstilling av en forbindelse med formel I, hvor R^ betyr en med lavere alkyl mono- eller di-substituert aminogruppe, alkylerer en forbindelse med formelen IX g) for the preparation of a compound of formula I, where R 1 means a lower alkyl mono- or di-substituted amino group, alkylates a compound of formula IX
hvor R, R1, R2, R^ og n hfcr de i formel I angitte betydninger og en av substituentene R^ og R^ er hydrogen og den annen hydrogen eller lavere alkyl, where R, R1, R2, R^ and n have the meanings given in formula I and one of the substituents R^ and R^ is hydrogen and the other hydrogen or lower alkyl,
eventuelt for fremstilling av en optisk enhetlig forbindelse med formel I spalter opp et tilsvarende racemat eller anvender et optisk enhetlig utgangsmateriale, eller optionally for the preparation of an optically uniform compound of formula I cleaves a corresponding racemate or uses an optically uniform starting material, or
eventuelt skiller for fremstilling av et enkelt racemat av en forbindelse som inneholder minst to asymmetrisentre en tilsvarende diastereoisomerblanding, eller eventuelt for fremstilling av et syreaddisjonssalt av en forbindelse med formelen I behand-...ler en tilsvarende fri base med en uorganisk eller organisk syre. optionally separates for the preparation of a single racemate of a compound containing at least two asymmetric centers a corresponding diastereoisomer mixture, or optionally separates for the preparation of an acid addition salt of a compound with the formula I-...treats a corresponding free base with an inorganic or organic acid.
a) Ifolge en forste fremgangsmåte-modifikasjon erholder man således forbindelser med formel I, ved at man cykliserer en a) According to a first method modification, compounds of formula I are thus obtained by cyclizing one
forbindelse med ovennevnte formel II. Denne cykliseringen skj er i nærvær av et surt kondensasjonsmiddel, hvorved - alt efter substituentens egenart - f.eks. saltsyre, svovelsyre,. fosforsyre, polyfosforsyre, bortrifluorid, aluminiumklorid, tinntetraklorid osv. kan anvendes. Ved valg av et surt kondensasjonsmiddel må man ta hensyn til at alt efter reaksjonsbetingelsene kan de eventuelle nærværende alkoksygruppene R og/eller R^ overgå i hydroksygrupper ved eterspaltning eller forbli uforandret. I mange tilfeller kan det være fordelaktig å gjennomfore cykliseringsreaksjonen i nærvær av et opplosningsmiddel. Reaksjonstemperaturen kan ifolge de ovrige reaksjonsbetingelser variere innen vide grenser, hvorved et temperaturom-råde mellom 10° og 150° er foretrukket. compound with the above-mentioned formula II. This cyclization takes place in the presence of an acidic condensation agent, whereby - depending on the nature of the substituent - e.g. hydrochloric acid, sulfuric acid,. phosphoric acid, polyphosphoric acid, boron trifluoride, aluminum chloride, stannous tetrachloride, etc. can be used. When choosing an acidic condensing agent, it must be taken into account that, depending on the reaction conditions, any alkoxy groups R and/or R^ present may change into hydroxy groups by ether cleavage or remain unchanged. In many cases, it can be advantageous to carry out the cyclization reaction in the presence of a solvent. The reaction temperature can, according to the other reaction conditions, vary within wide limits, whereby a temperature range between 10° and 150° is preferred.
b) Ifolge en annen fremgangsmåte-modifikasjon erholder man forbindelser med formel I, hvor R betyr halogen eller nitro b) According to another process modification, compounds of formula I are obtained, where R means halogen or nitro
eller en lavere alkyl med disubstituert aminogruppe, ved at man lavere alkylerer eller aralkylerer en forbindelse med ovenstående formel III. Innfbringen av alkyl- hhv. aralkyl-gruppen i 2-stiIling i isokinolin-strukturen skjer f.eks. ved omsetning av utgangsproduktet med formel III med et egnet alkyl- hhv. ar-alkylhalogenid, såsom metyljodid, etylbromid, benzylbromid; or a lower alkyl with a disubstituted amino group, by lower alkylating or aralkylating a compound of the above formula III. The introduction of alkyl or The aralkyl group in 2-styling in the isoquinoline structure takes place e.g. by reacting the starting product with formula III with a suitable alkyl or ar-alkyl halide such as methyl iodide, ethyl bromide, benzyl bromide;
med et tilsvarende sulfat, såsom dimetylsulfat5 eller med en egnet sulfonsyreester, som f.eks. benzensulfonsyremetylester, p-toluensulfonsyrebenzylester o.l. Men det er også mulig forst å innfore i 2-stilling i isokinolin-strukturen en alkanoyl-, benzoyl- hhv. fenylalkanoyl-gruppe, f.eks. ved hjelp av acetanhydrid, acetylklorid, benzoylklorid o.l., og redusere disse til slutt ved hjelp av litiumaluminiumhydrid til tilsvarende alkyl- hhv. aralkyl-gruppen. En metylgruppe kan også innfores på fordelaktig måte ved at man behandler forbindelsen med formel III med formaldehyd og maursyre, eller med formaldehyd og deref-feer med katalytisk aktivert hydrogen. Valget av en bestemt alkylerings- hhv. aralkyleringsmetode avhenger naturligvis av alkyl- hhv. aralkyl-resten som skal innfores, with a corresponding sulfate, such as dimethyl sulfate5 or with a suitable sulfonic acid ester, such as e.g. benzenesulfonic acid methyl ester, p-toluenesulfonic acid benzyl ester etc. But it is also possible first to introduce in the 2-position in the isoquinoline structure an alkanoyl, benzoyl or phenylalkanoyl group, e.g. with the help of acetic anhydride, acetyl chloride, benzoyl chloride etc., and finally reduce these with the help of lithium aluminum hydride to the corresponding alkyl or the aralkyl group. A methyl group can also be advantageously introduced by treating the compound of formula III with formaldehyde and formic acid, or with formaldehyde and derivatives with catalytically activated hydrogen. The choice of a specific alkylation or aralkylation method naturally depends on the alkyl or the aralkyl residue to be introduced,
og av de i utgangsproduktet nærværende substituenter, slik at f.eks. eventuelle nærværende hydroksygrupper (R og/eller R^) likeledes alkyleres eller de angripes ikke. Det kan likeledes inntreffe en aralkylering, som skulle kunne fore til uonskede produkter, og dette må unngås. and of the substituents present in the starting product, so that e.g. any hydroxy groups present (R and/or R^) are likewise alkylated or they are not attacked. Aralkylation can also occur, which could lead to unwanted products, and this must be avoided.
c) Ifolge en ytterligere modifisert fremgangsmåte erholder man forbindelser med formel I, hvor R^ betyr halogen eller en med c) According to a further modified method, compounds of formula I are obtained, where R 1 means halogen or one with
lavere alkyl disubstituert aminogruppe, R og R£ får ikke være hydroksy og R^ får ikke være benzyl, ved at man reduserer en forbindelse med ovenstående formel IV under sure betingelser. Under disse sure reaksjonsbetingelsene kan en dehydratisering finne sted under dannelse av en forbindelse med formel V. lower alkyl disubstituted amino group, R and R£ must not be hydroxy and R^ must not be benzyl, by reducing a compound of the above formula IV under acidic conditions. Under these acidic reaction conditions, a dehydration can take place to form a compound of formula V.
En slik forbindelse kan under sure betingelser disproporsjonere til en forbindelse med formel I og til et tilsvarende isokinolinsalt. Det sistnevnte kan på sin side reduseres til en forbindelse med formel I. Reduksjonen av forbindelser med formel IV skjer, som sagt, under sure betingelser, f.eks. i iseddik, salt-syrer av forskjellig konsentrasjon, alkoholisk klorhydrogen osv. Som reduksjonsmiddel anvender man ved de to utforelses-formene av denne fremgangsmåte-modifikasjonen katalytisk aktivert hydrogen, hvorved man som hydreringskatalysatorer kan anvende f.eks. platinoksyd, blandinger av platinoksyd og platinsvart, rodium (på kull eller aluminiumoksyd) og spesielt palladium (på kull). Reduksjon av isokinolinsalt, som fåes som mellomprodukt, kan foretas med komplekse metallhydrider såsom alkalimetallhydrider, fortrinnsvis natriumborhydrid, eller med katalytisk aktivert hydrogen. Such a compound can, under acidic conditions, disproportionate to a compound of formula I and to a corresponding isoquinoline salt. The latter can in turn be reduced to a compound of formula I. The reduction of compounds of formula IV takes place, as said, under acidic conditions, e.g. in glacial acetic acid, hydrochloric acids of different concentrations, alcoholic hydrogen chloride, etc. In the two embodiments of this method modification, catalytically activated hydrogen is used as a reducing agent, whereby as hydrogenation catalysts you can use e.g. platinum oxide, mixtures of platinum oxide and platinum black, rhodium (on charcoal or alumina) and especially palladium (on charcoal). Reduction of the isoquinoline salt, which is obtained as an intermediate product, can be carried out with complex metal hydrides such as alkali metal hydrides, preferably sodium borohydride, or with catalytically activated hydrogen.
d) Ifolge ytterligere en modifisert fremgangsmåte erholder man forbindelser med formel I, hvor R^ betyr halogen eller d) According to a further modified method, compounds of formula I are obtained, where R^ means halogen or
eventuelt lavere alkyl med mono- eller disubstituert aminogruppe, og hvor R^ ikke får være benzyl, ved at man reduserer en forbindelse med ovenstående formel VT. Ved denne reduksjonen, som utfores ved hjelp av litiumaluminiumhydrid, må man ta hensyn til at en i utgangsmaterialet nærværende nitrogruppe ikke kan bibeholdes da denne overfores i den tilsvarende aminogruppen. Reaksjonen gjennomfores i et for reduksjon ved hjelp av litiumaluminiumhydrid egnet, inert, organiskt - •' opplosningsmiddel, f. eks. i ikke-cyklisk eller cyklisk eter, som f.eks. dietyleter, tetrahydrofuran, dioksan o.l. optionally lower alkyl with a mono- or disubstituted amino group, and where R^ must not be benzyl, by reducing a compound with the above formula VT. In this reduction, which is carried out using lithium aluminum hydride, it must be taken into account that a nitro group present in the starting material cannot be retained as this is transferred to the corresponding amino group. The reaction is carried out in an inert organic solvent suitable for reduction using lithium aluminum hydride, e.g. in non-cyclic or cyclic ether, such as diethyl ether, tetrahydrofuran, dioxane, etc.
Ytterligere modifiserte fremgangsmåter innen rammen av den nærværende oppfinnelse vedrorer modifikasjoner med substituenter i forbindelser med formel I. Further modified methods within the scope of the present invention relate to modifications with substituents in compounds of formula I.
e) Således kan man f.eks. erholde en forbindelse med formel I, hvor restene R og/eller R^ betyr lavere alkoksy, ved å foreta e) Thus, one can e.g. obtain a compound of formula I, where the radicals R and/or R 1 mean lower alkoxy, by carrying out
en sur eterspaltning og således erholde en tilsvarende forbindelse med formel I, hvor R og/eller R^ betyr.hydroksy. Eter-spaltningen gjennomfores f.eks. ved oppvarming i ca. 48%'ig bromhydrogenlosning. an acidic ether cleavage and thus obtain a corresponding compound of formula I, where R and/or R^ means hydroxy. The ether cleavage is carried out e.g. by heating for approx. 48% hydrogen bromide solution.
f) Videre er det mulig å redusere en forbindelse med formel I, hvor R4 betyr en nitrogruppe og R^ ikke er benzyl, til f) Furthermore, it is possible to reduce a compound of formula I, where R 4 means a nitro group and R 4 is not benzyl, to
en tilsvarende forbindelse med formel I, hvor R4 betyr en aminogruppe. Herved anvender man som reduksjonsmiddel f.eks. naszerende eller katalytisk aktivert hydrogen, litiumaluminiumhydrid osv. Reaksjonsn gjennomfores på kjent måte. a corresponding compound of formula I, where R 4 means an amino group. In this way, a reducing agent is used, e.g. nasing or catalytically activated hydrogen, lithium aluminum hydride, etc. The reaction is carried out in a known manner.
g) Forbindelser med formel I, hvor R^ betyr en aminogruppe, kan ved monoalkylering overfores i de tilsvarende forbindelser g) Compounds of formula I, where R^ means an amino group, can be converted into the corresponding compounds by monoalkylation
med formel I, hvor R4 betyr en lavere alkyl med monosubstituert aminogruppe. På analog måte kan forbindelser med formel I, hvor R4 betyr en lavere alkyl med monosubstituert aminogruppe, overfores i de tilsvarende forbindelser med formel I, hvor R . betegner en lavere alkyl med disubstituert aminogruppe. Denne reaksjonen gjennomfores ifolge kjente metoder, hvorved valget av en bestemt metode blant annet avhenger av de ovrige substituentene i molekylet. Således er det f.eks. mulig å velge reaksjonsbetingelser slik at eventuelt nærværende hydroksygrupper ikke blir angrepet. of formula I, where R 4 means a lower alkyl with a monosubstituted amino group. In an analogous manner, compounds of formula I, where R 4 means a lower alkyl with a monosubstituted amino group, can be converted into the corresponding compounds of formula I, where R . denotes a lower alkyl with disubstituted amino group. This reaction is carried out according to known methods, whereby the choice of a particular method depends, among other things, on the other substituents in the molecule. Thus, it is e.g. possible to choose reaction conditions so that any hydroxy groups present are not attacked.
Forbindelser med formel I, hvor minst en av symbolene R og Compounds of formula I, where at least one of the symbols R and
R^ betyr en benzyloksy og hvor R^ ikke er benzyl, gir ved en hydrogenolytisk debenzylering tilsvarende forbindelser med formel I, hvor minst et av symbolene R og R^ betyr hydroksy, R^ means a benzyloxy and where R^ is not benzyl, a hydrogenolytic debenzylation gives corresponding compounds of formula I, where at least one of the symbols R and R^ means hydroxy,
og hvor R^ ikke får være benzyl og R4 ikke får være nitro. and where R 4 must not be benzyl and R 4 must not be nitro.
Ifolge ytterligere en modifisert fremgangsmåte kan man According to a further modified method, one can
innen rammen av nærværende oppfinnelse erholde optisk ensartede forbindelser med formel I, ved at man spalter opp et tilsvarende racemat. Forbindelser med formel I oppviser nemlig minst et asymmetrisk sentrum, nemlig karbonatomet i 4- within the scope of the present invention obtain optically uniform compounds of formula I, by splitting up a corresponding racemate. Compounds of formula I exhibit at least one asymmetric center, namely the carbon atom in the 4-
stilling i isokinolin-strukturen. Denne racematspaltning skjer ifolge vanlige metoder, dvs. ved omsetning av racematet med en egnet, optisk, aktiv syre, separering av de begge erholdte diastereoisomere saltene, f.eks. ved fraksjonert krystallisasjon, og til slutt frigjoring av den optisk ensartede basen. position in the isoquinoline structure. This racemate cleavage takes place according to usual methods, i.e. by reaction of the racemate with a suitable, optically active acid, separation of the two diastereoisomeric salts obtained, e.g. by fractional crystallization, and finally liberation of the optically uniform base.
En annen,mulighet for fremstilling av en optisk ensartet forbindelse består i å anvende et optisk ensartet utgangsmateriale, fortrinnsvis ved å anvende en ifolge kjente metoder oppdelt forbindelse med formel III. Another possibility for producing an optically uniform compound consists in using an optically uniform starting material, preferably by using a compound of formula III separated according to known methods.
Forbindelser med formel I, som oppviser mer enn et asymmetrisk sentrum, kan forekomme i forskjellige diastereoisomere former. Ifolge ytterligere en modifisert fremgangsmåte kan, innen rammen av nærværende oppfinnelse blandinger av slike diastereoisomerer oppdeles ved hjelp av alminnelige og vanlige separasjonsmetoder i de enkelte racemater, som på sin side, Compounds of formula I, which exhibit more than one asymmetric center, may exist in various diastereoisomeric forms. According to a further modified method, within the scope of the present invention, mixtures of such diastereoisomers can be separated by means of ordinary and usual separation methods into the individual racemates, which in turn,
og som tidligere nevnt, naturligvis kan oppdéles i sine optisk, enhetlige komponenter. and as previously mentioned, can of course be divided into its optically uniform components.
Forbindelser med formel I er basiske substanser, og fremstillingen av deres syreaddisjonssalter, og da spesielt slike som er farmasøytisk anvendbare, omfattes likeledes av nærværende oppfinnelse. Disse saltene kan fremstilles av de tilsvarende basene ifolge ålment kjente metoder ved omsetning med egnede uorganiske eller organiske syrer. Eksempler på organiske og uorganiske syrer, som anvendes for fremstilling av Compounds of formula I are basic substances, and the production of their acid addition salts, and especially those that are pharmaceutically usable, is also covered by the present invention. These salts can be prepared from the corresponding bases according to widely known methods by reaction with suitable inorganic or organic acids. Examples of organic and inorganic acids, which are used for the production of
farmasoytisk anvendbare salter er: klor- eller bromhydrogen-'"-syre, svovelsyre, eddiksyre, ravsyre, maleinsyre, metan-, benzen-eller p-toluensulfonsyre osv. Farmasoytiske ikke anvendbare syreaddisjonssalter av forbindelser med formel I egner seg som mellomprodukter ved fremstillingen av tilsvarende farmasoytisk anvendbare syreaddisjonssalter, og dette kan skje ved omsaltning eller ved frigjoring av basen og derefter saltdannelse med en egnet syre. pharmaceutically usable salts are: chloric or bromohydrogen acid, sulfuric acid, acetic acid, succinic acid, maleic acid, methane, benzene or p-toluenesulfonic acid, etc. Pharmaceutically non-usable acid addition salts of compounds of formula I are suitable as intermediates in the preparation of corresponding pharmaceutically usable acid addition salts, and this can be done by resalting or by releasing the base and then forming a salt with a suitable acid.
De ifolge analogifremgangsmåtene som utgangsprodukter They follow the analogical procedures as output products
anvendte forbindelser, kan fremstilles efter kjente metoder. used compounds, can be produced according to known methods.
I efterfolgende reaksjonsskjema er noen representative eksempler In the following reaction scheme are some representative examples
for fremstilling av slike utgangsprodukter angitt. Naturligvis må disse syntese-veier for fremstilling av andre substituerte forbindelser modifiseres tilsvarende. for the manufacture of such output products indicated. Naturally, these synthesis routes for the production of other substituted compounds must be modified accordingly.
1,2,3,4-tetrahydro-4-fenylisokinolin-derivater med formel I viser en antidepressiv virkning. For å påvise dette ble det undersokte preparatet administrert til grupper på hver 5 rotter i tre doser på hver 50 mg/kg p.o. (to ganger dagen for og en gang forsoksdagen). 6 timer efter.den siste administrasjonen ble dyrene injisert subkutant med 20 mg/kg 2-hydroksy-2-etyl-3-isobutyl-9,lO-dimetoksy-1,3,4,6,7,llb-heksahydro-2H-benzo[a]kinolizin-hydroklorid. Den samme dose ble administrert til en gruppe på 5 ikke-forbehandlede rotter. Bedom-melsen omfattet sentrale og perifere symptomer, og som er karakteristiske for antidepressiva [sml. Ann. N.Y. Acad. Sei. 96, 279 (1962)]. Man observerte spesiell motilitet (klatring), irritasjonsomtålighet, opphevelse av ptosis og videre med hensyn til å forholde seg sokende. Disse forandringer ble uttrykt i tall ifolge en bedommelsesskala. 1,2,3,4-tetrahydro-4-phenylisoquinoline derivatives of formula I show an antidepressant effect. To demonstrate this, the investigated preparation was administered to groups of 5 rats each in three doses of 50 mg/kg p.o. (twice the day before and once the day of the trial). 6 hours after the last administration, the animals were injected subcutaneously with 20 mg/kg 2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H- benzo[a]quinolizine hydrochloride. The same dose was administered to a group of 5 non-pretreated rats. The assessment included central and peripheral symptoms, which are characteristic of antidepressants [cf. Ann. NEW. Acad. Pollock. 96, 279 (1962)]. One observed special motility (climbing), tolerance to irritation, elimination of ptosis and further with regard to behaving in a searching manner. These changes were expressed in numbers according to a rating scale.
De i den efterfolgende tabell I angitte forbindelser viser f.eks. ved dette forsok en sterk antidepressiv virkning, og som gir seg uttrykk i en sterk okt, karakteristisk motilitet, irritasjonsomtålighet, sokende attityde såvel som fullstendig opphevelse av ptosis. De angitte prosenttall er basert på The compounds listed in the following table I show e.g. by this tried a strong anti-depressant effect, and which is expressed in a strong oct, characteristic motility, tolerance of irritation, searching attitude as well as complete abolition of ptosis. The indicated percentages are based on
den med amitriptylin erholdte verdien (Amitriptylin = 100%). the value obtained with amitriptyline (Amitriptyline = 100%).
Den lave toksisiteten av forbindelser med formel I kan illustreres med den akutte toksisiteten av de i tabell 1 angitte forbindelser på.mus (24 timers-verdi). The low toxicity of compounds of formula I can be illustrated by the acute toxicity of the compounds listed in Table 1 on mice (24 hour value).
FORSO KSRAP PORT FORSO KSRAP PORT
Endring av Ro 4- 1284 syndrom Change of Ro 4- 1284 syndrome
Den folgende test benyttes for å undersSke imipraminlignende antidepressiv virkning hos forbindelser. The following test is used to examine the imipramine-like antidepressant effect of compounds.
Grupper på fem rotter får forsoksforbindelsen oralt 29, 22 og 6 timer for subkutan injeksjon av 2o mg/kg 2-hydroksy-2-etyl-3-isobutyl-9,lo-dimetoksy-1,2,3,4,6,7-heksahydro-llbH-benzo /~a7kinolin-hydroklorid (Ro 4-1284) i en dosering på enten loo eller 5o eller 25 mg/kg. De 5 dyrene holdes sammen i bur på 35 x 25 x 2o cm. Groups of five rats receive the test compound orally at 29, 22 and 6 hours before subcutaneous injection of 20 mg/kg 2-hydroxy-2-ethyl-3-isobutyl-9,10-dimethoxy-1,2,3,4,6,7 -hexahydro-llbH-benzo /~a7quinoline hydrochloride (Ro 4-1284) in a dosage of either loo or 5o or 25 mg/kg. The 5 animals are kept together in cages of 35 x 25 x 20 cm.
De folgende symptom blir bedomt og gitt poeng ved 15, 3o, 45, 6o, 9o og 12o minutter etter Ro 4-1284 administrering: The following symptoms are assessed and scored at 15, 3o, 45, 6o, 9o and 12o minutes after Ro 4-1284 administration:
1) Antall klatrende dyr (x2) : o - lo 1) Number of climbing animals (x2) : o - lo
2) Lokomotorisk aktivitet - redusert aktivitet : o 2) Locomotor activity - reduced activity: o
- normal aktivitet : 1 - normal activity: 1
- bket aktivitet : 2 - active activity: 2
3) byenbredde - blepharospasme : o 3) city width - blepharospasm : o
- normal byenbredde : 1 - normal city width: 1
- exophtalmus : 2 - exophthalmos : 2
n n
4) Reaksjon på mekaniske stimuli - normal reaksjon : o 4) Reaction to mechanical stimuli - normal reaction : o
- moderat okning av reaksjonen : 1 - moderate increase in the reaction: 1
- tydelig okning av reaksjonen : 2 - clear increase in the reaction: 2
Det totale poengtall ved hver observasjon plottes mot tiden og det oppnådde areal bestemmes planimetrisk. Virkningen av den provede forbindelsen blir gitt som prosentdel av det området som bestemmes planimetrisk etter oral administrering av imip-ramin 3 x 5o mg/kg. The total number of points for each observation is plotted against time and the area obtained is determined planimetrically. The effect of the test compound is given as a percentage of the area determined planimetrically after oral administration of imipramine 3 x 50 mg/kg.
Sammenfatning Summary
Forbindelsene fremstilt ifolge oppfinnelsen oppviser et hdyere nivå av antidepressiv virkning enn forbindelsene ifolge teknikkens stand. Dette er demonstrert ved det faktum at de relativt svakt aktive forbindelsene ifolge oppfinnelsen, dvs. forbindelsene I og J er allerede mer enn 30% mer aktive enn forbindelsene ifolge teknikkens stand, dvs. forbindelsene M, N The compounds produced according to the invention exhibit a higher level of antidepressant action than the compounds according to the state of the art. This is demonstrated by the fact that the relatively weakly active compounds according to the invention, i.e. the compounds I and J are already more than 30% more active than the compounds according to the state of the art, i.e. the compounds M, N
og 0. Overlegenheten blir enda klarere når de meget aktive forbindelsene fremstilt ifolge oppfinnelsen, dvs. and 0. The superiority becomes even clearer when the highly active compounds produced according to the invention, i.e.
4-(3, 4-diklorfenyl)-1, 2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline
4-(3, 4-diklorfenyl)-1,2,3,4-tetrahydrO-2-metyl-7-isokinolinol 4-(4-klorfenyl)-1,2,3,4-tetrahydro-2-metyl-7-isokinolinol 4-(3, 4-dichlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7 -isoquinolinol
tas i betraktning, hvor forbindelser er 50% mer aktive enn forbindelsene M, N og 0 ifolge teknikkens stand. are taken into account, where compounds are 50% more active than compounds M, N and 0 according to the state of the art.
Fremgangsmåteproduktene som fremstilles ifolge fremgangsmåten kan finne anvendelse som legemiddel, f.eks. i form.av farma-søytiske preparater, og som sådanne eller i form av deres salter forekommer i blanding med en for den enterale, f.eks. orale eller parenterale administrasjonen egnede farmasøytiske, organiske eller uorganiske inerte bærematerialer, som f.eks. vann, gelatin, melkesukker, stivelse, magnesiumstearat, talkum, vegetabilsk olje, gummi arabicum, polyalkylenglykol, vaselin osv. De farmasøytiske preparatene kan foreligge i form av f.eks. tabeletter, dragéer, suppositorier, kapsler, eller i flytende form, f.eks. som losninger, suspensjoner eller emulsjoner. Eventuelt er de sterilisert og hhv. eller inneholder hjelpe-stoffer, som konserverings-, stabiliserings-, fuktnings- eller emulgeringsmidler, salter for forandring av det osmotiske trykket eller puffer. De kan også inneholde andre terapeutisk verdifulle stoffer. The method products produced according to the method can be used as medicine, e.g. in the form of pharmaceutical preparations, and as such or in the form of their salts occur in a mixture with one for the enteral, e.g. pharmaceutical, organic or inorganic inert carrier materials suitable for oral or parenteral administration, such as e.g. water, gelatin, milk sugar, starch, magnesium stearate, talc, vegetable oil, gum arabic, polyalkylene glycol, vaseline, etc. The pharmaceutical preparations can be in the form of e.g. tablets, dragées, suppositories, capsules, or in liquid form, e.g. as solutions, suspensions or emulsions. If necessary, they are sterilized and resp. or contains auxiliary substances, such as preservatives, stabilisers, wetting or emulsifying agents, salts for changing the osmotic pressure or buffers. They may also contain other therapeutically valuable substances.
Hensiktsmessige farmasoytiske doseringsformer inneholder 1 til 200 mg av en forbindelse med formel I. Hensiktsmessige orale doseringsområder for pattedyr ligger 0,1 mg/kg pr. Appropriate pharmaceutical dosage forms contain 1 to 200 mg of a compound of formula I. Appropriate oral dosage ranges for mammals are 0.1 mg/kg per
dag til 5 mg/kg pr. dag. Hensiktsmessige parenterale doseringsdoser for pattedyr ligger ved 0,1 mg/kg pr. dag day to 5 mg/kg per day. Appropriate parenteral dosing doses for mammals are at 0.1 mg/kg per day
"til 1,0 mg/kg pr. dag. De nevnte doser kan imidlertid "to 1.0 mg/kg per day. However, the mentioned doses can
okes eller minskes, alt efter det individuelle behovet og fagmannens anbefalinger. can be increased or decreased, depending on individual needs and the specialist's recommendations.
I de efterfolgende eksempler, som nærmere skal forklare oppfinnelsen, angis alle temperaturer i Celsiusgrader. In the following examples, which will explain the invention in more detail, all temperatures are given in degrees Celsius.
EKSEMPEL 1 EXAMPLE 1
Man frisetter basen fra 1,55 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid, opptar denne under rysting med 1,1 ml av en 35%'ig formaldehydlosning og lar den stå til henstand 2 timer ved romtemperatur. Man hydrerer over 1 g Raney-nikkel, filtrerer fra katalysatoren, inndamper filtratet og krystalliserer resten med etanolisk hydrogenklorid, metanol og eter. Omkrystallisering fra metanol-eter gir 1,50 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin-hydroklorid med smp. 244 - 246°. The base is liberated from 1.55 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride, this is taken up while shaking with 1.1 ml of a 35% formaldehyde solution and leave it to rest for 2 hours at room temperature. One hydrates over 1 g of Raney nickel, filters from the catalyst, evaporates the filtrate and crystallizes the residue with ethanolic hydrogen chloride, methanol and ether. Recrystallization from methanol-ether gives 1.50 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride with m.p. 244 - 246°.
Utgangsproduktet kan f.eks. fremstilles som folger: The output product can e.g. produced as follows:
Man fremstiller av 4-klorbenzaldehyd cyanhydrinet og reduserer dette ved hjelp av litiumaluminiumhydrid til rac-oc- (amino-metyl)-4-klorbenzylalkohol. The cyanohydrin is prepared from 4-chlorobenzaldehyde and this is reduced with the help of lithium aluminum hydride to rac-oc-(amino-methyl)-4-chlorobenzyl alcohol.
Man frisetter av 41,6 g rac-oc- (aminometyl)-4-klorbenzylalkohol-hydroklorid, opptar den i 400 ml benzen, tilsetter 30 g 3-metoksybenzaldehyd og oppvarmer blandingen under tilbakelop ved anvendelse av en vannavskiller inntil alt vannet er fjernet. Derefter inndamper man, oppldser resten i 400 ml metanol, tilsetter under isavkjoling i små porsjoner. 15 g natriumborhydrid og rorer blandingen i 6 timer ved romtemperatur. Inndampning, utrysting, krystallisasjon med etanolisk hydrogenklorid, metanol og eter og omkrystallisasjon i metanol - eter, gir 49,5 g rac-4-klor-a-£[ (3-metoksybenzyl)aminojmetyl} benzylalkohol-hydroklorid med smp. 198 - 199°. 41.6 g of rac-oc-(aminomethyl)-4-chlorobenzyl alcohol hydrochloride are liberated, taken up in 400 ml of benzene, 30 g of 3-methoxybenzaldehyde are added and the mixture is heated under reflux using a water separator until all the water has been removed. It is then evaporated, the residue dissolved in 400 ml of methanol, added under ice-cooling in small portions. 15 g of sodium borohydride and stir the mixture for 6 hours at room temperature. Evaporation, shaking off, crystallization with ethanolic hydrogen chloride, methanol and ether and recrystallization in methanol - ether gives 49.5 g of rac-4-chloro-α-£[(3-methoxybenzyl)aminojmethyl} benzyl alcohol hydrochloride with m.p. 198 - 199°.
Den frie basen viser efter omkrystallisasjon i eter-petroleter et smp. på 88 - 90°. After recrystallization in ether-petroleum ether, the free base shows a m.p. at 88 - 90°.
91,0 g rac-4-klor-a-£[0-metoksybenzyl)amino]metyl}benzylalkohol-hydroklorid rores under argon i en time med 1450 ml av en blanding av 1 volumdel svovelsyre (d=l,84) og 1 volumdel vann ved 100°. Efter avkjoling helles blandingen på ca. 10 kg is og 1,1 kg natriumhydroksyd og ekstraheres med metylenklorid. De med mettet natriumkloridlosning vaskede ekstrakter gir efter 91.0 g of rac-4-chloro-α-£[0-methoxybenzyl)amino]methyl}benzyl alcohol hydrochloride is stirred under argon for one hour with 1450 ml of a mixture of 1 part by volume of sulfuric acid (d=1.84) and 1 volume fraction of water at 100°. After cooling, the mixture is poured into approx. 10 kg of ice and 1.1 kg of sodium hydroxide and extracted with methylene chloride. The extracts washed with saturated sodium chloride solution yield
tbrkning og inndampning ca. 78 g av en mbrkegul olje. absorption and evaporation approx. 78 g of a dark yellow oil.
Kromatografi av denne oljen på 7 kg kieselgel gir 2 hovedfraksjoner. Den forste gir efter tilsetning av etanolisk hydrogenklorid, krystallisasjon med eddikester og eter og omkrystallisasjon i metanol-eter 22,0 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-5-metoksyisokinolin-hydroklorid med smp. Chromatography of this oil on 7 kg silica gel gives 2 main fractions. The first gives, after addition of ethanolic hydrogen chloride, crystallization with ethyl acetate and ether and recrystallization in methanol-ether, 22.0 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-5-methoxyisoquinoline hydrochloride with m.p.
236 - 238°. ' 236 - 238°. '
Den andre fraksjonen gir efter analog behandling 43,6 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid med smp. 200 - 202°. - ' The second fraction gives, after analogous treatment, 43.6 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride with m.p. 200 - 202°. - '
EKSEMPEL 2 EXAMPLE 2
Av 12,2 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid frigjores basen og rores med 150 ml 48%'ig hydrogenbromid-3osning i 2 timer ved en badtemperatur på 160° ved tilbakelop. Efter inndampning og omkrystallisasjon i metanol-eter erholder man 13,1 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-2-metyl-7-isokinolinol-hydrobromid med smp. 292 - 293°. Den derav frisatte base viser efter omkrystallisasjon i eter et smp. på. 189 - 190°, og det med 'etanolisk hydrogenklorid dannede og i metanol-eter omkrystalliserte hydrokloridet har smp. 295 - 297°. From 12.2 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride, the base is liberated and stirred with 150 ml of 48% hydrogen bromide solution for 2 hours at a bath temperature of 160° at reflux. After evaporation and recrystallization in methanol-ether, 13.1 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol hydrobromide are obtained with m.p. 292 - 293°. The resulting base shows, after recrystallization in ether, a m.p. on. 189 - 190°, and the hydrochloride formed with ethanolic hydrogen chloride and recrystallized in methanol ether has m.p. 295 - 297°.
EKSEMPEL 3 EXAMPLE 3
Man frigjor basen av 8,0 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid, opptar den i 150 ml metanol, tilsetter 6 ml av en 35%'ig formaldehydopplosning og ryster inntil det dannede bunnfallet er fullstendig opplost. Derefter hydrerer man over 6 g Raney-nikkel filtrerer og krystalliserer efter surgjbring med etanolisk hydrogenklorid. Omkrystallisering av metanol-eter gir 8,3 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid med smp. 250 - 251°. The base of 8.0 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride is released, it is taken up in 150 ml of methanol, 6 ml of a 35% formaldehyde solution and shake until the precipitate formed is completely dissolved. It is then hydrated over 6 g of Raney nickel filters and crystallized after acidification with ethanolic hydrogen chloride. Recrystallization from methanol-ether gives 8.3 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride with m.p. 250 - 251°.
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Man fremstiller av 3-klorbenzaldehyd cyanhydrin, og reduserer dette ved hjelp av litiumaluminiumhydrid til rac-a-(aminometyl)-3-klorbenzylalkohol. Cyanohydrin is produced from 3-chlorobenzaldehyde, and this is reduced with the help of lithium aluminum hydride to rac-α-(aminomethyl)-3-chlorobenzyl alcohol.
Man frigjor av 18,5 g rac-a-(aminometyl)-3-klorbenzylalkohol-hydroklorid b^sen, opptar den i 200 ml benzen, tilsetter 13,4 g 3-metoksybenzaldehyd og oppvarmer ved anvendelse av tilbakelop <p>g en vannavskiller til alt vann er fjernet. 18.5 g of rac-a-(aminomethyl)-3-chlorobenzylalcohol hydrochloride is released, it is taken up in 200 ml of benzene, 13.4 g of 3-methoxybenzaldehyde is added and heated using reflux <p>g a water separator until all water is removed.
Derefter inndamper man, opploser resten i 300 ml metanol, tilsetter under isavkjoling 8 g natriumborhydrid, lar dette stå 18 timer og inndamper. Efter å ha rystet ut og surgjort med etanolholdig klorhydrogen og efter omkrystallisasjon i metanol-eter, erholder man 23,2 g rac-3-klor-a--[[ (3-metoksybenzyl) amino] metyl} benzylalkohol-hydroklorid med smp. 174 - 175°. Den frie basen viser efter omkrystallisasjon i eter-petroleter et smp. på 98 - 100°. It is then evaporated, the residue is dissolved in 300 ml of methanol, 8 g of sodium borohydride are added under ice-cooling, this is allowed to stand for 18 hours and evaporated. After shaking out and acidifying with ethanol-containing hydrogen chloride and after recrystallization in methanol-ether, 23.2 g of rac-3-chloro-α-[[(3-methoxybenzyl)amino]methyl}benzyl alcohol hydrochloride with m.p. 174 - 175°. After recrystallization in ether-petroleum ether, the free base shows a m.p. of 98 - 100°.
30,0 g rac-3-klor~a-|[ (3-metoksybenzyl)amino]metyl| -benzylalkohol-hydroklorid omrores 2 timer ved 100° i en blanding av like deler kons. svovelsyre og vann. Den avkjolte losningen heller man til en blanding av is og natriumhydroksyd (overskudd av alkali) og ekstraherer med metylenklorid. Ved kromatografering ved hjelp av silikagel separeres to ensartede stoffer, som krystalliserer efter surgjoring med etanolholdig klorhydrogen og tilsetning av eter. Omkrystallisasjonen av den ene fraksjonen i metanol-eter gir 7,2 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-5-metoksy-isokinolin-hydroklorid med smp. 230 - 232°. Den derav fremstilte basen viser efter omkrystallisasjon i eter-petroleter et smp. på 93 - 95°. Den andre fraksjonen gir efter analog opparbeidelse 14,1 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid med smp. 217 - 219°. 30.0 g rac-3-chloro~a-|[(3-methoxybenzyl)amino]methyl| -benzyl alcohol hydrochloride is stirred for 2 hours at 100° in a mixture of equal parts conc. sulfuric acid and water. The cooled solution is poured into a mixture of ice and sodium hydroxide (excess alkali) and extracted with methylene chloride. Chromatography using silica gel separates two uniform substances, which crystallize after acidification with ethanol-containing hydrogen chloride and addition of ether. The recrystallization of one fraction in methanol-ether gives 7.2 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-5-methoxy-isoquinoline hydrochloride with m.p. 230 - 232°. The resulting base shows, after recrystallization in ether-petroleum ether, a m.p. of 93 - 95°. The second fraction gives, after analogous work-up, 14.1 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride with m.p. 217 - 219°.
EKSEMPEL 4 EXAMPLE 4
Den av 4,00 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid frigjorte basen oppvarmes 1 time med 80 ml 48%'ig bromhydrogensyre ved 150° (badtemperatur). Efter inndampning rystes dette ut med eddikester og natriumbikarbonat-losning. Ved å surgjdre eddikester-ekstraktet med etanolholdig klorhydrogen og ved krystallisasjon og omkrystallisasjon i metanol-eter erholder man 3,72 g rac-4-(3-klorfenyl)-1,2,3,4-tetrahydro-2-metyl-7-isokinolinol-hydroklorid med smp. The base liberated from 4.00 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride is heated for 1 hour with 80 ml of 48% hydrobromic acid at 150 ° (bath temperature). After evaporation, this is shaken out with vinegar and sodium bicarbonate solution. By acidifying the acetic ester extract with ethanolic hydrogen chloride and by crystallization and recrystallization in methanol-ether, 3.72 g of rac-4-(3-chlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7- isoquinolinol hydrochloride with m.p.
258 - 259°. Den derav frigjorte basen viser efter omkrystallisasjon i eter-petroleter et smp. på 196 - 197°. 258 - 259°. The base released therefrom shows, after recrystallization in ether-petroleum ether, a m.p. of 196 - 197°.
EKSEMPEL 5 EXAMPLE 5
Man frigjor av 19 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksyisokinolin-hydroklorid basen, opptar den med 300 ml metanol og 15 ml 35%'ig formalinlosning, og lar dette stå ved romtemperatur 2 timer. Efter hydrering over Raney-nikkel, tilsetning av etanolisk klorhydrogen og omkrystallisasjon i metanol-eter, erholder man 18,7 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metylisokinolin-hydroklorid med smp. 190 - 220°. Den frie basen krystalliserer i eter-petroleter og har smp. 101 - 102°, The base is released from 19 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline hydrochloride, it is taken up with 300 ml of methanol and 15 ml of a 35% formalin solution, and let this stand at room temperature for 2 hours. After hydration over Raney nickel, addition of ethanolic hydrogen chloride and recrystallization in methanol-ether, 18.7 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy- 2-methylisoquinoline hydrochloride with m.p. 190 - 220°. The free base crystallizes in ether-petroleum ether and has m.p. 101 - 102°,
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Man fremstiller av 4-klorbenzaldehyd cyanhydrin, og reduserer dette med litiumaluminiumhydrid til rac-a-(amino-metyl)-4-klorbenzylalkohol. Cyanohydrin is produced from 4-chlorobenzaldehyde, and this is reduced with lithium aluminum hydride to rac-α-(amino-methyl)-4-chlorobenzyl alcohol.
Man frigjor av 6,0 g rac-a-(aminometyl)-4-klorbenzyl-alkohol-hydroklorid basen, opptar den i 200 ml benzen og koker en time med 5,3 g veratrumaldehyd under anvendelse av en vannavskiller og tilbakelop. Den efter inndampningen erholdte resten tas opp i 200 ml metanol og reduseres ved 5° med 2,5 g natriumborhydrid. Efter inndampning, utrystning, surgjoring med etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter, erholder man 9,6 g rac-4-klor-a- \ J_ (3,4-dimetoksybenzyl) aminojmetyl} benzylalkohol-hydroklorid med smp. 220 - 221°. The base is liberated from 6.0 g of rac-α-(aminomethyl)-4-chlorobenzyl alcohol hydrochloride, taken up in 200 ml of benzene and boiled for one hour with 5.3 g of veratrum aldehyde using a water separator and reflux. The residue obtained after evaporation is taken up in 200 ml of methanol and reduced at 5° with 2.5 g of sodium borohydride. After evaporation, shaking, acidification with ethanol-containing hydrogen chloride and recrystallization in methanol-ether, 9.6 g of rac-4-chloro-α- (3,4-dimethoxybenzyl) aminojmethyl} benzyl alcohol hydrochloride with m.p. 220 - 221°.
Den frie basen viser efter omkrystallisasjon i eter-petroleter The free base shows after recrystallization in ether-petroleum ether
ét smp. på 93 - 94°. one m.p. at 93 - 94°.
Ved romtemperatur og under omroring tilsetter man 7,12 g rac-4-klor-a-|[(3,4-dimetoksybenzyl)aminojmetyl}benzylalkohol-hydroklorid i 100 ml av en blanding av like volumdeler kons. svovelsyre og vann, og derefter oppvarmes dette 30 minutter ved 80°. Efter å ha gjort alkalisk, rystet ut basen med metylenklorid, surgjort med etanolholdig klorhydrogen og omkrystallisasjon i etanol-eter, erholder man 5,7 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksyisokinolin-hydroklorid med smp. 186 - 187°. Den frigjorte basen viser efter omkrystallisasjon i eter et smp. på 118 - 119°. At room temperature and with stirring, 7.12 g of rac-4-chloro-α-|[(3,4-dimethoxybenzyl)aminojmethyl}benzyl alcohol hydrochloride are added to 100 ml of a mixture of equal parts conc. sulfuric acid and water, and this is then heated for 30 minutes at 80°. After making alkaline, shaking off the base with methylene chloride, acidifying with ethanolic hydrogen chloride and recrystallization in ethanol-ether, 5.7 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6 are obtained ,7-dimethoxyisoquinoline hydrochloride with m.p. 186 - 187°. The liberated base shows, after recrystallization in ether, a m.p. of 118 - 119°.
EKSEMPEL 6 EXAMPLE 6
Den av 1,80 g rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metylisokinolin-hydroklorid frigjorte basen omrores 3 timer med 30 ml 48%'ig bromhydrogen-losning ved 150° The base liberated from 1.80 g of rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline hydrochloride is stirred for 3 hours with 30 ml of 48% hydrogen bromide - unloading at 150°
(badtemperatur). Efter inndampning og omkrystallisasjon i metanol-eter erholder man 1,85 g rac-4(4-klorfenyl)-1,2,3,4-tetrahydro-2-metyl-6,7-isokinolindiol-hydrobromid med smp. (bath temperature). After evaporation and recrystallization in methanol-ether, 1.85 g of rac-4(4-chlorophenyl)-1,2,3,4-tetrahydro-2-methyl-6,7-isoquinoindiol hydrobromide are obtained with m.p.
280 - 281°. 280 - 281°.
EKSEMPEL 7 EXAMPLE 7
Den av 5,20 g rac-4-(3,4-diklorfenyl)-1,2,3, 4-tetrahydro-7-metoksyisokinolin-hydroklorid frigjorte basen omrores 2 timer med 75 ml metanol og 3,8 ml 35%'ig formaldehydlbsning og derefter hydrert over 2 g Ifeney-nikkel. Efter filtrering, inndampning, surgjoring med etanolisk klorhydrogen, krystallisasjon og omkrystallisasjon i metanol-eter erholder man 5,00 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin-hydroklorid med smp. 2 73 - 2 75°. The base released from 5.20 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride is stirred for 2 hours with 75 ml of methanol and 3.8 ml of 35% ig formaldehyde solution and then hydrated over 2 g of Ifeney nickel. After filtration, evaporation, acidification with ethanolic hydrogen chloride, crystallization and recrystallization in methanol-ether, 5.00 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2 is obtained -methylisoquinoline hydrochloride with m.p. 2 73 - 2 75°.
Utgangsproduktet kan f.eks. fremstilles som folger: The output product can e.g. produced as follows:
Man fremstiller av 3,4-diklorbenzaldehyd cyanhydrin og Cyanohydrin and
reduserer dette med litiumaluminiumhydrid eller man reduserer tx-klor-3 ,4-dikloracetof enon med natriumborhydrid, og omsetter det erholdte klorhydrin med ammoniakk, hvorved man i begge tilfelle får rac-a- (aminometyl)-3,4-diklorbenzylalkohol. this is reduced with lithium aluminum hydride or tx-chloro-3,4-dichloroacetof enone is reduced with sodium borohydride, and the resulting chlorohydrin is reacted with ammonia, whereby in both cases rac-a-(aminomethyl)-3,4-dichlorobenzyl alcohol is obtained.
Av 70,0 g rac-a-(aminometyl)-3,4-diklorbenzylalkohol-hydroklorid frigjores basen, og dette oppvarmes 2 timer i en liter benzen med 40,8 g 3-metoksybenzaldehyd under tilbakelop og anvendelse av en vannavskiller til ikke mer vann kan fjernes. The base is liberated from 70.0 g of rac-α-(aminomethyl)-3,4-dichlorobenzyl alcohol hydrochloride, and this is heated for 2 hours in one liter of benzene with 40.8 g of 3-methoxybenzaldehyde under reflux and using a water separator until no more water can be removed.
Efter inndampning og opplosning i 1 liter .metanol reduseres After evaporation and dissolution in 1 liter of methanol is reduced
med 30 g natriumborhydrid under en temperatur på 5°, hvorefter man inndamper og ryster ut med metylenklorid og vann. Det med etanolholdig klorhydrogen surgjorte metylenklorid-ekstraktet krystalliserer med eddikester, og gir efter omkrystallisasjon i metanol-eter 104 g rac-3,4-diklor-a-£[ (3-metoksybenzyl)amino] metyl}benzylalkohol-hydroklorid med smp. 198 - 200°. Den i metanol-petroleter omkrystalliserte frie basen viser et smp. with 30 g of sodium borohydride under a temperature of 5°, after which one evaporates and shakes out with methylene chloride and water. The methylene chloride extract acidified with ethanolic hydrogen chloride crystallizes with ethyl acetate, and after recrystallization in methanol ether yields 104 g of rac-3,4-dichloro-a-£[(3-methoxybenzyl)amino]methyl}benzyl alcohol hydrochloride with m.p. 198 - 200°. The free base recrystallized in methanol-petroleum ether shows a m.p.
på 94 - 95°. at 94 - 95°.
100 g rac-3,4-diklor-oc-£[ (3-metoksybenzyl) aminojmetyl} - benzylalkohol-hydroklorid tilsettes under omroring til 1 liter av en blanding av 1 volumdel svovelsyre (d = 1,84) og 1 volumdel vann og oppvarmes derefter 8 timer på et bad ved 100°. Efter avkjoling heller man blandingen til en avkjolt losning bestående av 1 kg natriumhydroksyd i isvann, og ryster derefter ut med metylenklorid. Kromatografering av ekstraktet (80 g råprodukt) ved hjelp av 4 kg silikagel gir ifolge tynn-skiktskromatogrammene 2 ensartede hovedfraksjoner. Surgjoring med etanolholdig HCl, krystallisasjon med eddikester og omkryttallisasjon i metanol-eter gir 19,8 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-5-metoksyisokinolin-hydroklorid 'med smp. 255 - 256° og 45,1 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid med smp. 243 - 244°. 100 g of rac-3,4-dichloro-oc-£[(3-methoxybenzyl)aminojmethyl}-benzyl alcohol hydrochloride is added with stirring to 1 liter of a mixture of 1 part by volume of sulfuric acid (d = 1.84) and 1 part by volume of water and is then heated for 8 hours in a bath at 100°. After cooling, the mixture is poured into a cooled solution consisting of 1 kg of sodium hydroxide in ice water, and then shaken out with methylene chloride. Chromatography of the extract (80 g of crude product) using 4 kg of silica gel gives, according to the thin-layer chromatograms, 2 uniform main fractions. Acidification with ethanolic HCl, crystallization with acetic ester and recrystallization in methanol-ether gives 19.8 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-5-methoxyisoquinoline hydrochloride with m.p. 255 - 256° and 45.1 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride with m.p. 243 - 244°.
EKSEMPEL 8 EXAMPLE 8
Basen frigjores av 2,00 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid og oppvarmes ved tilbakelop i en time med 48%'ig bromhydrogen-losning ved en badtemperatur på 160°. Efter inndampning og omkrystallisasjon av metanol-eter erholder man 2,0 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-2-metyl-7-isokinolinol-hydrobromid med smp. 284 - 285°. Den derav med metylenklorid og natriumbikarbonatlosning frigjorte basen viser efter omkrystallisasjon i eter-petroleter smp. The base is liberated from 2.00 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride and heated at reflux for one hour with 48% hydrogen bromine solution at a bath temperature of 160°. After evaporation and recrystallization of methanol-ether, 2.0 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol hydrobromide with m.p. 284 - 285°. The base liberated therefrom with methylene chloride and sodium bicarbonate solution shows, after recrystallization in ether-petroleum ether, m.p.
212 - 212,5°, og det med etanolholdig klorhydrogen erholdte hydrokloridet viser efter omkrystallisasjon i metanol-eter smp. 287 - 288° (spaltning, sintrer ved 2 80°). 212 - 212.5°, and the hydrochloride obtained with ethanolic hydrogen chloride shows, after recrystallization in methanol-ether, m.p. 287 - 288° (decomposition, sinters at 2 80°).
EKSEMPEL 9 EXAMPLE 9
Den av 11,6 g rac-1,2,3, 4-tetrahydro-7-metoksy-4-(4-nitrofenyl)-isokinolin-hydroklorid frigjorte basen oppvarmes med 14 ml maursyre og 14 ml 35%'ig formaldehydlosning 1 time under The base liberated from 11.6 g of rac-1,2,3,4-tetrahydro-7-methoxy-4-(4-nitrophenyl)-isoquinoline hydrochloride is heated with 14 ml of formic acid and 14 ml of 35% formaldehyde solution for 1 hour under
tilbakelop. Efter inndampning i vakuum, utrystning mellom metylenklorid og natriumbikarbonat-lbsning, tilsetning av den organiske fasen med etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter erholder man 10,2 g nesten hvitt rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4-(4-nitrofenyl)isokinolin-hydroklorid med smp. 250 - 251° (spaltning). backflow. After evaporation in vacuum, shaking between methylene chloride and sodium bicarbonate solution, addition of the organic phase with ethanol-containing hydrogen chloride and recrystallization in methanol-ether, 10.2 g of almost white rac-1,2,3,4-tetrahydro-7-methoxy is obtained -2-methyl-4-(4-nitrophenyl)isoquinoline hydrochloride with m.p. 250 - 251° (decomposition).
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Man bromerer 4-nitroacetofenon i oc-stilling, reduserer det Bromination of 4-nitroacetophenone in the oc position reduces it
erholdte produktet med natriumborhydrid til det tilsvarende bromhydrinet, og behandler dette med ammoniakk, hvorved man erholder rac-a-(aminometyl)-4-nitrobenzylalkohol med smp. 138 - obtained the product with sodium borohydride to the corresponding bromohydrin, and treats this with ammonia, thereby obtaining rac-α-(aminomethyl)-4-nitrobenzyl alcohol with m.p. 138 -
139° (i eddikester) .._ 4 g rac-a-(aminometyl)-4-nitrobenzylalkohol i 50 ml benzen kokes med 3,4 g 3-metoksybenzaldehyd under tilbakelop og ved å anvende en vannavskiller til ikke mere vann kan fjernes. Efter inndampning reduseres produktet i 200 ml metanol under iskjoling med tilsammen 2 g natriumborhydrid, og dette kokes endelig 1 time ved romtemperatur. Man erholder efter inndampning, 139° (in acetic ester) .._ 4 g of rac-α-(aminomethyl)-4-nitrobenzyl alcohol in 50 ml of benzene are boiled with 3.4 g of 3-methoxybenzaldehyde under reflux and by using a water separator until no more water can be removed. After evaporation, the product is reduced in 200 ml of methanol under ice cooling with a total of 2 g of sodium borohydride, and this is finally boiled for 1 hour at room temperature. One obtains after evaporation,
utrystning med metylenklorid og vann, surgjoring med etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter 6,9 g rac-a-£[ (3-metoksy-benzyl)aminojmetyl} -4-nitrobenzylalkohol- shaking off with methylene chloride and water, acidification with ethanolic hydrogen chloride and recrystallization in methanol-ether 6.9 g rac-α-£[ (3-methoxy-benzyl)aminojmethyl}-4-nitrobenzylalcohol-
hydroklorid med smp. 248 - 249°. Den frie basen viser efter omkrystallisasjon i eter-petroleter et smp. på 117 - 119°. hydrochloride with m.p. 248 - 249°. After recrystallization in ether-petroleum ether, the free base shows a m.p. of 117 - 119°.
51 g rac-a-^[ (3-metoksybenzyl)aminojmety]} -4-nitro-benzylalkohol-hydroklorid oppvarmes 1/2 time med 125 ml polyfosfor- 51 g of rac-a-^[(3-methoxybenzyl)aminojmethyl]}-4-nitro-benzyl alcohol hydrochloride is heated for 1/2 hour with 125 ml of polyphosphor-
syre ved 100°. Efter tilsetning av is og efter å ha gjort losningen alkalisk med natriumkarbonat, ekstraheres losningen med metylenklorid. Efter inndampning av den organiske fasen erholder man 43 g rodbrun olje. Kromatografi ved hjelp av 3,5 acid at 100°. After adding ice and after making the solution alkaline with sodium carbonate, the solution is extracted with methylene chloride. After evaporation of the organic phase, 43 g of red-brown oil is obtained. Chromatography using 3.5
kg silikagel og med eter-cykloheksan-dietylamin 40:10:1 gir to rene hovedfraksjoner, som efter tilsetning av etanolholdig kg of silica gel and with ether-cyclohexane-diethylamine 40:10:1 gives two pure main fractions, which after addition of ethanol-containing
klorhydrogen og eddikester krystalliserer. Man erholder efter omkrystallisasjon i metanol-eter 9,9 g svakt gul rac-1,2,3,4-tetrahydro-5-metoksy-4-(4-nitrofenyl)isokinolin-hydroklorid med smp. 260 - 261° (den frie basen viser smp. 159°) og 12,5 g svakt gul rac-1,2,3,4-tetrahydro-7-metoksy-4-(4-nitrofenyl)isokinolin-hydroklorid med smp. 225 - 226°. hydrogen chloride and acetic acid crystallize. After recrystallization in methanol-ether, 9.9 g of slightly yellow rac-1,2,3,4-tetrahydro-5-methoxy-4-(4-nitrophenyl)isoquinoline hydrochloride with m.p. 260 - 261° (the free base shows m.p. 159°) and 12.5 g of pale yellow rac-1,2,3,4-tetrahydro-7-methoxy-4-(4-nitrophenyl)isoquinoline hydrochloride with m.p. 225 - 226°.
EKSEMPEL 10 EXAMPLE 10
Den av 2,0 g rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4-(4-nitrofenyl)isokinolin-hydroklorid frigjorte basen hydreres i 200 ml metanol med 200 ml platinoksyd ved romtemperatur og atmosfæretrykk. Efter å ha tilsatt etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter erholder man 2,1 g rac-4-(4-aminofenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-dihydroklorid med smp. 250 - 255°. (Sintring ved 210°). The base released from 2.0 g of rac-1,2,3,4-tetrahydro-7-methoxy-2-methyl-4-(4-nitrophenyl)isoquinoline hydrochloride is hydrated in 200 ml of methanol with 200 ml of platinum oxide at room temperature and atmospheric pressure. After adding ethanolic hydrogen chloride and recrystallization in methanol-ether, 2.1 g of rac-4-(4-aminophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline dihydrochloride are obtained with m.p. 250 - 255°. (Sintering at 210°).
EKSEMPEL 11 EXAMPLE 11
Av 4,5 g rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4-(4-nitro-fenyl)isokinolin-hydroklorid frigjores basen, og denne rores med 60 ml 48%'ig bromhydrogen-losning 1 1/2 time ved 150° The base is liberated from 4.5 g of rac-1,2,3,4-tetrahydro-7-methoxy-2-methyl-4-(4-nitro-phenyl)isoquinoline hydrochloride, and this is stirred with 60 ml of 48% hydrogen bromide solution 1 1/2 hours at 150°
(badtemperatur). Efter inndampning, utrystning med eddikester og natriumbikarbonatlosning, surgjoring med etanolholdig (bath temperature). After evaporation, shaking out with vinegar and sodium bicarbonate solution, acidification with ethanol-containing
•'klorhydrogen og omkrystallisasjon i metanol-eter erholder man 4,2 g nesten fargelos rac-1,2,3,4-tetrahydro-2-metyl-4-(4-nitrofenyl)-7-isokinolinol-hydroklorid med smp. 263 - 265° •'chlorohydrogen and recrystallization in methanol ether yield 4.2 g of almost colorless rac-1,2,3,4-tetrahydro-2-methyl-4-(4-nitrophenyl)-7-isoquinolinol hydrochloride with m.p. 263 - 265°
(spaltning). (fission).
EKSEMPEL 12 EXAMPLE 12
Den av 13,5 g rac-1,2,3,4-tetrahydro-7-metoksy-4-(3-iritrofenyl)-isokinolin-hydroklorid frigjorte basen oppvarmes med 15,9 ml maursyre og 16,7 ml 35%'ig formaldehydlosning 1 time ved 120° The base released from 13.5 g of rac-1,2,3,4-tetrahydro-7-methoxy-4-(3-erythrophenyl)-isoquinoline hydrochloride is heated with 15.9 ml of formic acid and 16.7 ml of 35% ig formaldehyde solution for 1 hour at 120°
(badtemperatur). Efter inndampning, utrystning med metylenklorid og natriumbikarbonatlosning, surgjoring med etanolholdig klorhydrogen, krystallisasjon og omkrystallisasjon i metanol-eter erholder man 9,5 g svakt brunt rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4- (3-nitrofenyl)isokinolin-hydroklorid med smp. 247 - 248° (sintring ved 239°). (bath temperature). After evaporation, shaking with methylene chloride and sodium bicarbonate solution, acidification with ethanolic hydrogen chloride, crystallization and recrystallization in methanol-ether, 9.5 g of slightly brown rac-1,2,3,4-tetrahydro-7-methoxy-2-methyl-4 are obtained - (3-nitrophenyl)isoquinoline hydrochloride with m.p. 247 - 248° (sintering at 239°).
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Man bromerer 3-nitroacetofenon i oc-stilling, reduserer bromeringsproduktet ved hjelp av natriumborhydrid til det tilsvarende bromhydrinet, og behandler dette med ammoniakk. Man erholder rac-a- (aminometyl)-3-nitrobenzylalkohol, som 3-nitroacetophenone is brominated in the oc position, the bromination product is reduced using sodium borohydride to the corresponding bromohydrin, and this is treated with ammonia. Rac-α-(aminomethyl)-3-nitrobenzyl alcohol is obtained, which
efter omkrystallisasjon i eddikester-eter smelter ved 107 - after recrystallization in acetate ether melts at 107 -
108° (sintring ved 105°). 108° (sintering at 105°).
38,3 g rac-a-(aminometyl)-3-nitrobenzylalkohol kokes med 32,5 38.3 g of rac-α-(aminomethyl)-3-nitrobenzyl alcohol is boiled with 32.5
g 3-metoksybenzaldehyd i 500 ml benzen under tilbakelop med vannavskiller til ikke mere vann kan fjernes. Efter inndampning opptas resten i 1,5 liter metanol, og dette tilsettes under omroring og iskjoling suksessivt 20 g natriumborhydrid, hvorefter man rorer ennå 3 timer ved romtemperatur. Utrystning med metylenklorid-vann, surgjoring med etanolholdig klorhydrogen, krystallisasjon og omkrystallisasjon i metanol-eter gir 63,8 g of 3-methoxybenzaldehyde in 500 ml of benzene under reflux with a water separator until no more water can be removed. After evaporation, the residue is taken up in 1.5 liters of methanol, and to this is successively added, while stirring and cooling with ice, 20 g of sodium borohydride, after which stirring is continued for a further 3 hours at room temperature. Evaporation with methylene chloride-water, acidification with ethanol-containing hydrogen chloride, crystallization and recrystallization in methanol-ether gives 63.8
g rac-a-[[ (3-metoksybenzyl)aminojmetyl}-3-nitrobenzylalkohol-hydroklorid med smp. 193 - 195° (sintring ved 186°). g rac-α-[[ (3-methoxybenzyl)aminojmethyl}-3-nitrobenzyl alcohol hydrochloride with m.p. 193 - 195° (sintering at 186°).
55 g rac-a-(3-metoksybenzyl)aminojmetyl}-3-nitrobenzylalkohol-hydroklorid og 165 g polyfosforsyre (84,1% P2°5^ oppvarmes 45 minutter ved 100°. Efter tilsetning av noe is og eddikester gjores losningen alkalisk med natriumkarbonat og utrystes. Eddikesterekstraktet (46 g) kromatograferes ved hjelp av 3,7 55 g of rac-α-(3-methoxybenzyl)aminojmethyl}-3-nitrobenzyl alcohol hydrochloride and 165 g of polyphosphoric acid (84.1% P2°5^ are heated for 45 minutes at 100°. After adding some ice and acetic acid, the solution is made alkaline with sodium carbonate and shake off.The acetic ester extract (46 g) is chromatographed using 3.7
kg silikagel. Man eluerer med eter-aceton-dietylamin 19:1:1 kg silica gel. Elute with ether-acetone-diethylamine 19:1:1
og får to enhetlige hovedfraksjoner på hhv. 7,Og og 22,2g. Efter surgjoring med etanolholdig saltsyre, krystallisasjon bg omkrystallisasjon i metanol-eter erholder man av den fbrste fraksjonen et gulaktig rac-1,2-3,4-tetrahydro-5-metoksy-4-(3-nitrofenyl)isokinolin-hydroklorid med smp. 217 - 219°, og av den andre fraksjonen får man et brunaktig rac-1,2,3,4-tetrahydro-7-metoksy-4-(3-nitrofenyl)isokinolinhydroklorid med smp. 253 - 255°. and gets two uniform main fractions of respectively 7, And and 22.2g. After acidification with ethanolic hydrochloric acid, crystallization bg recrystallization in methanol-ether, a yellowish rac-1,2-3,4-tetrahydro-5-methoxy-4-(3-nitrophenyl)isoquinoline hydrochloride is obtained from the first fraction with m.p. 217 - 219°, and the second fraction gives a brownish rac-1,2,3,4-tetrahydro-7-methoxy-4-(3-nitrophenyl)isoquinoline hydrochloride with m.p. 253 - 255°.
EKSEMPEL 13 EXAMPLE 13
Den av 2,5 g rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4-(3-nitrofenyl)isokinolin-hydroklorid frigjorte basen opplbses i 250 ml metanol og hydreres 1/2 time med 250 mg platinoksyd. Efter surgjoring med etanolholdig klorhydrogen, krystallisasjon med eter og omkrystallisasjon i metanol-eter erholder man 2,1 g rac-4- (3-aminofenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin-dihydroklorid med smp. 250 - 251°. The base released from 2.5 g of rac-1,2,3,4-tetrahydro-7-methoxy-2-methyl-4-(3-nitrophenyl)isoquinoline hydrochloride is dissolved in 250 ml of methanol and hydrated for 1/2 hour with 250 mg platinum oxide. After acidification with ethanolic hydrogen chloride, crystallization with ether and recrystallization in methanol-ether, 2.1 g of rac-4-(3-aminophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline are obtained -dihydrochloride with m.p. 250 - 251°.
EKSEMPEL 14 EXAMPLE 14
Den av 4,0 g rac-1,2,3,4-tetrahydro-7-metoksy-2-metyl-4-(3-nitrofenyl)isokinolin-hydroklorid frigjorte basen oppvarmes 1 1/2 time med 60 ml 48%'ig bromhydrogenlosning ved 150° The base liberated from 4.0 g of rac-1,2,3,4-tetrahydro-7-methoxy-2-methyl-4-(3-nitrophenyl)isoquinoline hydrochloride is heated for 1 1/2 hours with 60 ml of 48% ig hydrogen bromine solution at 150°
(badtemperatur). Efter inndampning og utrystning mellom natriumbikarbonatlosning og eddikester, surgjoring med etanolholdig klorhydrogen, krystallisasjon med eter og omkrystallisasjon i metanol-eter erholder man rac-1,2,3,4-tetrahydro-2-metyl-4-(3-nitrofenyl)-7-isokinolinol-hydroklorid med smp. 257 - 258° (spaltning). (bath temperature). After evaporation and shaking between sodium bicarbonate solution and ethyl acetate, acidification with ethanolic hydrogen chloride, crystallization with ether and recrystallization in methanol-ether, rac-1,2,3,4-tetrahydro-2-methyl-4-(3-nitrophenyl)-7 is obtained -isoquinolinol hydrochloride with m.p. 257 - 258° (decomposition).
EKSEMPEL 15 EXAMPLE 15
Den av 3,7 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-6-metoksy-7-isokinolinol-hydroklorid frigjorte basen tilsettes 100 ml metanol og 5 ml 35%'ig formaldehydlosning. Efter 2 timers henstand av denne losningen ved romtemperatur hydreres med 5 g 100 ml of methanol and 5 ml of 35% formaldehyde release. After this solution has stood for 2 hours at room temperature, hydrate with 5 g
Raney-nikkel. Efter filtrering, inndampning og surgjoring med etanolholdig klorhydrogen erholder man et krystallisert produkt. Raney nickel. After filtration, evaporation and acidification with ethanol-containing hydrogen chloride, a crystallized product is obtained.
Omkrystallisasjon i metanol-eter gir 3,65 g rac-4-(3,4-diklor-fenyl)-1,2,3,4-tetrahydro-6-metoksy-2-metyl-7-isokinolinol-. hydroklorid med smp. 253 - 254°. Recrystallization in methanol-ether gives 3.65 g of rac-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-6-methoxy-2-methyl-7-isoquinolinol-. hydrochloride with m.p. 253 - 254°.
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Den av 20,0 g rac-a-(aminometyl)-3,4-diklorbenzylalkohol-hydroklorid frigjorte basen holdes i 500 ml benzen med 13,7 g isoyanillin (3-hydroksy-4-metoksybenzaldehyd) 1 1/2 time under tilbakelop, hvorved det avskilte vannet ved hjelp av en vannavskiller oppfanges. Efter kort tid utkrystalliserer det dannede iminet (smp. 149 - 150°). Efter inndampning av benzenet reduseres imin i 500 ml metanol med 10 g natriumborhydrid. Efter inndampning, utrystning med metylenklorid og vann, surgjoring med etanolholdig klorhydrogen, krystallisasjon og omkrystallisasjon i metanol erholder man 24,1 g rent rac-3,4-diklor-oc-\[ (3-hydroksy-4-metoksybenzyl) aminojmetyl} benzylalkohol-hydroklorid med smp. 230 - 231°. Den frie basen viser efter omkrystallisasjon i eter-petroleter et smp. på 119 - 120°. The base released from 20.0 g of rac-α-(aminomethyl)-3,4-dichlorobenzyl alcohol hydrochloride is kept in 500 ml of benzene with 13.7 g of isoaniline (3-hydroxy-4-methoxybenzaldehyde) for 1 1/2 hours under reflux , whereby the separated water is collected by means of a water separator. After a short time, the formed imine crystallizes (m.p. 149 - 150°). After evaporation of the benzene, the imine is reduced in 500 ml of methanol with 10 g of sodium borohydride. After evaporation, shaking with methylene chloride and water, acidification with ethanolic hydrogen chloride, crystallization and recrystallization in methanol, 24.1 g of pure rac-3,4-dichloro-oc-[(3-hydroxy-4-methoxybenzyl) aminojmethyl} benzyl alcohol is obtained -hydrochloride with m.p. 230 - 231°. After recrystallization in ether-petroleum ether, the free base shows a m.p. of 119 - 120°.
Til 14 g rac-3,4-diklor-a-^[ (3-hydroksy-4-metoksybenzyl)amino]-metyljbenzylalkohol-hydroklorid tilsetter man under kjoling i et isbad 40 ml kons. svovelsyre og ryster 5 minutter. Derefter tilsettes den klare losningen i is, losningen gjores alkalisk med natriumbikarbonat og rystes ut med metylenklorid. Efter surgjoring med etanolholdig klorhydrogen utkrystalliserer et ennå ikke-enhetlig stoff, som ennå en gang utrystes med eddikester og natriumbikarbonatlosning. Efter surgjoring og omkrystallisasjon i metanol-eter erholder man 5,5 g rent rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-6-metoksy-7-i sokinolinol-hydroklorid med smp. 257 - 258°. 40 ml of conc. sulfuric acid and shake for 5 minutes. The clear solution is then added to ice, the solution is made alkaline with sodium bicarbonate and shaken out with methylene chloride. After acidification with ethanol-containing hydrogen chloride, a still non-uniform substance crystallizes out, which is once again shaken with vinegar and sodium bicarbonate solution. After acidification and recrystallization in methanol-ether, 5.5 g of pure rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-6-methoxy-7-isoquinolinol hydrochloride are obtained with m.p. 257 - 258°.
EKSEMPEL 16 EXAMPLE 16
Den av 6,5 g rac-4- (3,-4-diklorfenyl) -1,2 ,3,4-tetrahydro-6,7-dimetoksyisokinolin-hydroklorid frigjorte basen oppvarmes med 10 ml maursyre og 10 ml 35%'ig formalinlosning 1 time"ved 120° The base liberated from 6.5 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline hydrochloride is heated with 10 ml of formic acid and 10 ml of 35% formalin solution 1 hour" at 120°
(badtemperatur) . Efter inndampning, utrystning med natrium-karbonatlosning og metylenklorid og surgjoring med etanolholdig klorhydrogen erholder man rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metyl-isokinolin-hydroklorid, (bath temperature) . After evaporation, shaking with sodium carbonate solution and methylene chloride and acidification with ethanolic hydrogen chloride, rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinoline is obtained -hydrochloride,
hvilket omkrystalliseres i metanol-eter og som derefter smelter ved 243 - 246° (sintring ved 238°). Den frie basen viser efter omkrystallisasjon i eter-petroleter et smp. på 115 - 116°. which is recrystallized in methanol-ether and which then melts at 243 - 246° (sintering at 238°). After recrystallization in ether-petroleum ether, the free base shows a m.p. of 115 - 116°.
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Av 7,0 g rac-a-(aminometyl)-3,4-diklor-benzylalkohol- From 7.0 g of rac-α-(aminomethyl)-3,4-dichloro-benzyl alcohol-
hydroklorid frigjores basen, som opptas i 100 ml benzen og kokes 1 time med 5,8 g veratrumaldehyd under anvendelse av en vannavskiller. Den efter inndampning erholdte resten opptas i 100 ml metanol og reduseres ved 5° med 3 g natriumborhydrid. Efter inndampning, utrysting, surgjoring med etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter erholder man 10,6 g rac-3,4-diklor-a-([(3T4-dimetoksybenzyl)amino]-metyl} hydrochloride, the base is released, which is taken up in 100 ml of benzene and boiled for 1 hour with 5.8 g of veratrum aldehyde using a water separator. The residue obtained after evaporation is taken up in 100 ml of methanol and reduced at 5° with 3 g of sodium borohydride. After evaporation, shaking, acidification with ethanol-containing hydrogen chloride and recrystallization in methanol-ether, 10.6 g of rac-3,4-dichloro-a-([(3T4-dimethoxybenzyl)amino]-methyl} are obtained
benzylalkohol-hydroklorid med smp. 209 - 210°. Den frie basen har efter omkrystallisasjon i eter-petroleter et smp. på benzyl alcohol hydrochloride with m.p. 209 - 210°. After recrystallization in ether-petroleum ether, the free base has a m.p. on
126 - 127°. 126 - 127°.
Ved romtemperatur og under omroring tilsetter man 9,5 g rac-3,4-diklor-oc- {[ (3,4-dimetoksybenzyl) aminojmetyl} benzylalkohol-hydroklorid til 100 ml av en blanding av like volumdeler kons. svovelsyre og vann, og dette oppvarmes derefter 60 minutter ved 100°. Efter å ha gjort alkalisk under iskjbling, utrystet basen med metylenklorid, surgjort med etanolholdig klorhydrogen og omkrystallisert i metanol-eddikester erholder man 6,5 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-isokinolin-hydroklorid med smp. 247 - 248° (sintring ved 240°). At room temperature and with stirring, 9.5 g of rac-3,4-dichloro-oc-{[ (3,4-dimethoxybenzyl) aminojmethyl} benzyl alcohol hydrochloride is added to 100 ml of a mixture of equal parts by volume conc. sulfuric acid and water, and this is then heated for 60 minutes at 100°. After making alkaline under ice-cooling, stripping the base with methylene chloride, acidifying with ethanolic hydrogen chloride and recrystallizing in methanol-acetic ester, 6.5 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro are obtained -6,7-dimethoxy-isoquinoline hydrochloride with m.p. 247 - 248° (sintering at 240°).
EKSEMPEL 17 EXAMPLE 17
Av 5,4 g av en blanding av de to diastereoisomerene av rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-l-metyl-isokinolin-hydroklorid (forhold ca. 3:2) frigjores basen. Den loses derefter i 100 ml metanol, og får derefter stå med 3,6 ml 35%'ig formaldehydlosning 3 timer ved romtemperatur. Til slutt hydreres over ca. 3 g Raney-nikkel. Man erholder 5,4 g av en From 5.4 g of a mixture of the two diastereoisomers of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-1-methyl-isoquinoline hydrochloride (ratio approx. 3:2) the base is released. It is then dissolved in 100 ml of methanol, and is then allowed to stand with 3.6 ml of 35% formaldehyde solution for 3 hours at room temperature. Finally, hydrate over approx. 3 g Raney nickel. One obtains 5.4 g of one
gul olje, som kromatograferes ved hjelp av silikagel og elueres med cykloheksan-eter-dietylamin 50:50:1. Herved fåes to hovedfraksjoner. Den forste krystalliserer i etanolholdig klorhydrogen og eter og gir 2,3 g av hydrokloridet av det ene av de to diastereoisomere rac-4- (3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-l,2-dimetylisokinolinet med smp. 253 - 255°. Den andre fraksjonen krystalliserer efter tilsetning av sitronsyre i metanol og gir efter omkrystallisasjon i metanol 2,3 g av citratet av det andre av de to diastereoisomere rac-4- (3 ,4-diklorf enyl).-l ,2 , 3 ,4-tetrahydro-7-metoksy-l, 2-dimetylisokinolin med smp. 175 - 176°. Efter frigjoring av basen av det nevnte citratet, surgjoring med etanolholdig klorhydrogen og omkrystallisasjon i metanol-eter erholder man det tilsvarende hydrokloridet med smp. 206 - 207°. yellow oil, which is chromatographed using silica gel and eluted with cyclohexane-ether-diethylamine 50:50:1. This results in two main factions. The first crystallizes in ethanolic hydrogen chloride and ether and gives 2.3 g of the hydrochloride of one of the two diastereoisomers rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-1 ,2-dimethylisoquinoline with m.p. 253 - 255°. The second fraction crystallizes after addition of citric acid in methanol and after recrystallization in methanol gives 2.3 g of the citrate of the second of the two diastereoisomers rac-4-(3,4-dichlorophenyl).-1,2,3,4 -tetrahydro-7-methoxy-1,2-dimethylisoquinoline with m.p. 175 - 176°. After liberation of the base from the aforementioned citrate, acidification with ethanol-containing hydrogen chloride and recrystallization in methanol-ether, the corresponding hydrochloride with m.p. 206 - 207°.
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
Den av 35,0 g rac-a-(aminometyl)-3,4-diklorbenzyl-alkohol-hydroklorid frigjorte basen oppvarmes med 22,5 g 3-metoksyaceto-fenon i 500 ml toluen 16 timer under tilbakelop, hvorved det avskilte vannet ved hjelp av en vannavskiller oppsamles. Efter inndampning tilsetter man 400 ml metanol, reduserer med til sammen IO g natriumborhydrid under iskjoling og rorer ennå 3 timer ved ca. 15°. Efter inndampning, utrysting med metylenklorid og vann, tilsetning av etanolholdig klorhydrogen, krystallisasjon i eddikester-petroleter og flere gangers omkrystallisasjon i metanol-eter erholder man 18 g av hydrokloridet av det ene av de to diastereoisomere racemiske 3,4-diklor-a-^[(3-metoksy-a-metylbenzyl)aminojmetyl} benzylalkohol med smp. 183 - 184°. Av moderluten krystalliserer efter utrysting med metylenklorid og 3-n natronlut og tilsetning av eter 13,1 g av den andre diastereomeren som fri base med smp. 80 - 81°. Dets hydroklorid viser efter omkrystallisasjon i metanol-eter > smp. 130 - 131°. The base released from 35.0 g of rac-α-(aminomethyl)-3,4-dichlorobenzyl alcohol hydrochloride is heated with 22.5 g of 3-methoxyacetophenone in 500 ml of toluene for 16 hours under reflux, whereby the separated water at with the help of a water separator is collected. After evaporation, add 400 ml of methanol, reduce with a total of 10 g of sodium borohydride under ice-cooling and stir for a further 3 hours at approx. 15°. After evaporation, shaking off with methylene chloride and water, addition of ethanol-containing hydrogen chloride, crystallization in ethyl acetate-petroleum ether and several times of recrystallization in methanol-ether, 18 g of the hydrochloride of one of the two diastereoisomeric racemic 3,4-dichloro-a-^ are obtained [(3-methoxy-α-methylbenzyl)aminojmethyl} benzyl alcohol with m.p. 183 - 184°. From the mother liquor, after shaking with methylene chloride and 3-n caustic soda and addition of ether, 13.1 g of the second diastereomer crystallizes as a free base with m.p. 80 - 81°. Its hydrochloride shows after recrystallization in methanol-ether > m.p. 130 - 131°.
10,4 g rac-3,4-diklor-a-£[(3-metoksy-a-metylbenzyl)-amino] metyl} -benzylalkohol (dtastereoisomer med smp. 80 - 81 ) oppvarmes 30 minutter i 55 ml polyfosforsyre under nitrogen ved 100°. 10.4 g of rac-3,4-dichloro-α-£[(3-methoxy-α-methylbenzyl)-amino] methyl}-benzyl alcohol (dtastereoisomer with m.p. 80 - 81 ) is heated for 30 minutes in 55 ml of polyphosphoric acid under nitrogen at 100°.
Derefter heller man reaksjonsblandingen til is, ryster ut med metylenklorid og 3-n natronlut og erholder 9,9 g av en oljeaktig base, som kromatograferes ved hjelp av 560 g silikagel. The reaction mixture is then poured into ice, shaken out with methylene chloride and 3-n caustic soda and 9.9 g of an oily base is obtained, which is chromatographed using 560 g of silica gel.
2 hovedfraksjoner elueres ved hjelp av cykloheksan-eter-dietylamin 25:25:1. Efter surgjoring med etanolholdig klorhydrogen, krystallisasjon og omkrystallisasjon i metanol-eter erholder man 2,5 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-5-metoksy-l-metyl-isokinolin-hydroklorid med smp. 243 - 244° 2 main fractions are eluted using cyclohexane-ether-diethylamine 25:25:1. After acidification with ethanolic hydrogen chloride, crystallization and recrystallization in methanol-ether, 2.5 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-5-methoxy-1-methyl-isoquinoline are obtained -hydrochloride with m.p. 243 - 244°
og 6,0 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-l-metylisokinolin-hydroklorid med smp. 179 - 180°. Den av det forste produktet frigjorte basen, dvs. det rac-4-(3,4-diklor-fenyl)-1,2,3,4-tetrahydro-5-metoksy-l-metylisokinolinet viser efter omkrystallisasjon i eter-petroleter smp. 70 - 71°. and 6.0 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-1-methylisoquinoline hydrochloride with m.p. 179 - 180°. The base liberated from the first product, i.e. the rac-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-5-methoxy-1-methylisoquinoline shows after recrystallization in ether-petroleum ether m.p. . 70 - 71°.
Ifolge kjerneresonans-spektrumet består det forste produktet According to the nuclear resonance spectrum, the first product consists of
av en blanding av like deler åv de to diastereoisomerene og det andre produktet består av en diastereoisomer-blanding i forholdet ca. 3:2. of a mixture of equal parts of the two diastereoisomers and the second product consists of a diastereoisomer mixture in the ratio approx. 3:2.
EKSEMPEL 18 EXAMPLE 18
1,00 g av hydrokloridet av den ene av de to diastereoisomere rac-3,4-diklor-a--[[ (3-metoksy-a-metylbenzyl) -amino] -metyl} benzylalkohol (smp. 183 - 184°) oppvarmes med 5 ml polyfosforsyre 1 time ved 100°. Efter å ha gjort alkalisk med natronlut drypper man ut med metylenklorid, inndamper, opploser i 20 ml metanol og lar det stå 2 timer med 1 ml 35%'ig formalinlosning. Ved hydrering over 1 g Raney-nikkel erholder man 950 mg av 1.00 g of the hydrochloride of one of the two diastereoisomers rac-3,4-dichloro-α-[[(3-methoxy-α-methylbenzyl)-amino]-methyl} benzyl alcohol (m.p. 183 - 184°) heated with 5 ml of polyphosphoric acid for 1 hour at 100°. After making alkaline with caustic soda, methylene chloride is added, evaporated, dissolved in 20 ml of methanol and left for 2 hours with 1 ml of 35% formalin solution. When hydrating over 1 g of Raney nickel, 950 mg of it is obtained
en nesten fargelos olje, som ifolge tynnfilmskromatogram består av to hoved- og to biprodukter. Kromatografi med 360 g silikagel og med cykloheksan-eter-dietylamin 50:50:1 gir som tredje substans en olje, av hvilken man efter surgjoring med etanolholdig klorhydrogen og krystallisasjon med metanol- an almost colorless oil, which, according to the thin-film chromatogram, consists of two main and two secondary products. Chromatography with 360 g of silica gel and with cyclohexane-ether-diethylamine 50:50:1 gives as the third substance an oil, from which, after acidification with ethanol-containing hydrogen chloride and crystallization with methanol
eter erholder 450 mg av hydrokloridet av det ene av de to rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-l,2-dimetyl-isokinolinet med smp. 218 - 220°. Efter omlosning i metanol-eter og poding med det ifolge eksempel 17 erholdte hydrokloridet med smp. 253 - 255° erholdes en annen krystallmodifikasjon med smp. 253 - 255°. ether obtains 450 mg of the hydrochloride of one of the two rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-1,2-dimethyl-isoquinoline with m.p. 218 - 220°. After redissolving in methanol-ether and grafting with the hydrochloride obtained according to example 17 with m.p. 253 - 255°, another crystal modification is obtained with m.p. 253 - 255°.
EKSEMPEL 19 EXAMPLE 19
a) Av 1,25 g av det i eksempel 17 erholdte rac-4-(3,4-diklor-fenyl)-1,2,3,4-tetrahydro-7-metoksy-l,2-dimetylisokinolin-hydrokloridet med smp. 253 - 255° frigjores basen, og dette oppvarmes med 30 ml 48%'ig bromhydrogenlosning 6 timer ved 150° a) From 1.25 g of the rac-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-7-methoxy-1,2-dimethylisoquinoline hydrochloride obtained in example 17 with m.p. . 253 - 255° the base is released, and this is heated with 30 ml of 48% hydrogen bromine solution for 6 hours at 150°
(badtemperatur). Efter inndampning og efter å ha gjort alkalisk med natriumbikarbonat utrystes med metylenklorid. (bath temperature). After evaporation and after making alkaline with sodium bicarbonate, shake out with methylene chloride.
Efter surgjoring med etanolholdig klorhydrogen, krystallisasjon After acidification with ethanolic hydrogen chloride, crystallization
i eddikester og omkrystallisasjon i metanol-eter erholder man 1,1 g av hydrokloridet av det ene av de to diastereoisomere rac-4-(3,4-diklorfenyl)-ly!,3,4-tetrahydro-l,2-dimetyl-7-isokinolinolene med smp. 254 - 255°. Utrysting méd natriumbikarbonat og metylenklorid gir den tilsvarende frie basen med smp. 180°. ' b) Den av 750 mg av det i eksempel 17 erholdte rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-l,2-dimetyl-isokinolin-hydrokloridet med smp. 206 - 207 frigjorte basen oppvarmes med 10 ml 48%'ig brpmhydrogenlosning 1 time ved 150 in ethyl acetate and recrystallization in methanol-ether yields 1.1 g of the hydrochloride of one of the two diastereoisomers rac-4-(3,4-dichlorophenyl)-ly!,3,4-tetrahydro-1,2-dimethyl- The 7-isoquinolinols with m.p. 254 - 255°. Shaking with sodium bicarbonate and methylene chloride gives the corresponding free base with m.p. 180°. b) Of the 750 mg of the rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-1,2-dimethyl-isoquinoline hydrochloride obtained in example 17 with m.p. . 206 - 207 the liberated base is heated with 10 ml of 48% brpmhydrogen solution for 1 hour at 150
(badtemperatur). Efter inndampning, utrysting med metylen- (bath temperature). After evaporation, shaking with methylene-
klorid og mettet natriumbikarbonat-ldsning, inndampning, surgjoring med etanolholdig saltsyre, krystallisasjon med eddikester og omkrystallisasjon i metanol-eter erholder man 710 mg av hydrokloridet av det andre av de to diastereoisomere rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-l,2-dimetyl-7-i sokinolinolene med smp. 254 - 255 . Den ved utrysting med metylenklorid og natriumbikarbonat frigbrte basen viser efter omkrystallisasjon. chloride and saturated sodium bicarbonate solution, evaporation, acidification with ethanolic hydrochloric acid, crystallization with acetic ester and recrystallization in methanol-ether gives 710 mg of the hydrochloride of the second of the two diastereoisomers rac-4-(3,4-dichlorophenyl)-1, The 2,3,4-tetrahydro-1,2-dimethyl-7-i soquinolinols with m.p. 254 - 255 . The base released by shaking with methylene chloride and sodium bicarbonate shows after recrystallization.
i eter-petroleter et smp. på 219 - 220°. in ether-petroleum ether a m.p. at 219 - 220°.
EKSEMPEL 20 EXAMPLE 20
Den av 3,1 g rac-4-(3 -4-diklorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metylisokinolin-hydroklorid i metylenklorid med natriumhydroksyd frigjorte basen oppvarmes 2 timer i lOO ml 48%'ig bromhydrogensyre ved en badtemperatur på 160° under tilbakelop. Allerede efter 1/2 time begynner krystallisasjonen under sterk skumdannelse. Efter kjoling tilsettes 80 ml vann. The base liberated from 3.1 g of rac-4-(3-4-dichlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline hydrochloride in methylene chloride with sodium hydroxide is heated for 2 hours in lOO ml of 48% hydrobromic acid at a bath temperature of 160° under reflux. Already after 1/2 hour, crystallization begins under strong foam formation. After cooling, add 80 ml of water.
Man avnutsjer og efter omkrystallisasjon i metanol-eter erholder man 2,6 g av hydrobromidet av rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-2-metyl-6,7-i.sokinolindiol med smp. 285 - 286°. It is filtered off and after recrystallization in methanol-ether, 2.6 g of the hydrobromide of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-2-methyl-6,7-i are obtained. soquinolinediol with m.p. 285 - 286°.
EKSEMPEL 21 EXAMPLE 21
1,50 g rac-3,4-diklor-a-[£(3-metoksybenzyl)metylamino]metyl} benzylalkohol-hydroklorid opploses i 20 ml av en blanding av 1 volumdel kons. svovelsyre og 1 volumdel vann under omristing og oppvarmet 1 1/2 time på et bad ved 100°. Efter å ha gjort alkalisk med 3-n NaOH under iskjoling utrystes med kloroform, torkes med Na2S0^ og inndampes i vakuum. Baseblandingen 1.50 g of rac-3,4-dichloro-α-[£(3-methoxybenzyl)methylamino]methyl} benzyl alcohol hydrochloride is dissolved in 20 ml of a mixture of 1 volume part conc. sulfuric acid and 1 part by volume of water with shaking and heated for 1 1/2 hours in a bath at 100°. After making alkaline with 3-n NaOH under ice-cooling, shake off with chloroform, dry with Na2S0^ and evaporate in vacuo. The base mixture
.kromatograferes derefter ved hjelp av 60 g silikagel (0,05-0,20 .is then chromatographed using 60 g of silica gel (0.05-0.20
mm) og ved hjelp av kloroform-dietylamin 99:1. Man eluerer efter hverandre 2 ifolge tynnfilmskromatogram enhetlige substanser, som efter surgjoring med etanolholdig saltsyre krystalliserer i eddikester. Efter omkrystallisasjon i metanol-eter erholder man fargelost rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-5-metoksy-2-metylisokinolin-hydroklorid med smp. 264 - 265° og fargelost rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid med smp. 273 - 275°. mm) and using chloroform-diethylamine 99:1. 2 uniform substances according to the thin-film chromatogram are eluted one after the other, which after acidification with ethanolic hydrochloric acid crystallize in acetic acid. After recrystallization in methanol-ether, colorless rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-5-methoxy-2-methylisoquinoline hydrochloride is obtained with m.p. 264 - 265° and colorless rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride with m.p. 273 - 275°.
Utgangsproduktet kan fremstilles som folger: The starting product can be produced as follows:
4,5 g rac-3,4-diklor-a-|[ (3-metoksybenzyl) aminojmetyl^benzylalkohol får stå 1 time ved romtemperatur i 100 ml metanol og 2,5 ml 35%'ig formaldehydlosning, hvorefter man hydrerer med Raney-nikkel. Efter å ha avnutsjet katalysatoren ved hjelp av diatomenjord, inndampning i vakuum, opplosning i eter, torking over natriumsulfat og på nytt inndampning tilsettes etanolholdig saltsyre. Derefter krystalliserer og omkrystalliserer man i etanol-eter. Man erholder 5,1 g fargelost rac-3,4-diklor-cc-^[ (3-metoksybenzyl)-metylamino]metyl] benzylalkohol-hydroklorid med smp. 166 - 167 . 4.5 g of rac-3,4-dichloro-α-|[ (3-methoxybenzyl) aminojmethyl^benzyl alcohol is allowed to stand for 1 hour at room temperature in 100 ml of methanol and 2.5 ml of a 35% formaldehyde solution, after which it is hydrated with Raney - nickel. After extracting the catalyst using diatomaceous earth, evaporation in a vacuum, dissolution in ether, drying over sodium sulphate and evaporation again, hydrochloric acid containing ethanol is added. It is then crystallized and recrystallized in ethanol-ether. 5.1 g of colorless rac-3,4-dichloro-cc-^[(3-methoxybenzyl)-methylamino]methyl] benzyl alcohol hydrochloride with m.p. 166 - 167 .
EKSEMPEL 22 EXAMPLE 22
Av 500 mg rac-4- (3,4-diklorfenyl-1,2,3,4-tetrahydro-7-iso-kinolinol-hydroklorid isoleres den frie basen ved utrystning med kloroform-eddikester 9:1 og natriumbikarbonatlosning. Efter opplosning i 15 ml metanol tilsettes 0,75 ml 35%'ig formaldehydlosning. Efter 2 timers henstand ved romtemperatur hydreres med 1 g Raney-nikkel. Efter filtrering, inndampning og surgjoring med etanolholdig saltsyre, krystallisasjon og omkrystallisasjon i metanol-eter erholder man de fargelbse rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-2-metyl-7-isokinolinol-hydrokloridet med smp. 287 - 288° (spaltning, sintring ved 280°). From 500 mg of rac-4-(3,4-dichlorophenyl-1,2,3,4-tetrahydro-7-iso-quinolinol hydrochloride), the free base is isolated by shaking with chloroform-acetic ester 9:1 and sodium bicarbonate solution. After dissolution in 15 ml of methanol is added to 0.75 ml of a 35% formaldehyde solution. After standing for 2 hours at room temperature, hydrate with 1 g of Raney nickel. After filtration, evaporation and acidification with ethanolic hydrochloric acid, crystallization and recrystallization in methanol-ether, the colored compounds are obtained The -4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-2-methyl-7-isoquinolinol hydrochloride with mp 287 - 288° (decomposition, sintering at 280°).
Utgangsmaterialet kan fremstilles på folgende måte: The starting material can be produced in the following way:
500 mg rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid oppvarmes med IO ml 48%'ig bromhydrogen-losning under nitrogen 2 timer ved en badtemperatur på 150° og under tilbakelop. Efter inndampning i vakuum og utrystning mellom kloroform-eddikester 9:1 og mettet natriumbikarbonatlosning tbrkes den organiske fasen, som derefter inndampes. Der-ved erholder man 300 mg fargelos rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-isokinolinol med smp. 243 - 244°. 500 mg of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride are heated with 10 ml of 48% hydrogen bromide solution under nitrogen for 2 hours at a bath temperature of 150° and below return flow. After evaporation in vacuum and shaking between chloroform-acetic ester 9:1 and saturated sodium bicarbonate solution, the organic phase is used, which is then evaporated. 300 mg of colorless rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-isoquinolinol with m.p. 243 - 244°.
Efter surgjoring med etanolholdig klorhydrogen og efter krystallisasjon og omkrystallisasjon i metanol-eter får man hydrokloridet med smp. 270 - 272°. After acidification with ethanol-containing hydrogen chloride and after crystallization and recrystallization in methanol-ether, the hydrochloride is obtained with m.p. 270 - 272°.
EKSEMPEL 2 3 EXAMPLE 2 3
10,0 g rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid tilsettes 100 ml etanol og oppvarmes med 4 g fast natriumhydroksyd og 12 g etylbromid 3 timer ved en badtemperatur på 100° under tilbakelop. Efter inndampning i vakuum utrystes dette med metylenklorid og 3-n natronlut og torkes over Na,,S04. Den ved inndampning erholdte basen tilsettes etanolholdig saltsyre, og efter krystallisasjon og omkrystallisasjon i metanol erholder man 9,5 g fargelost rac-4-(3,4-diklor-fenyl)-2-etyl-l,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid med smp. 269 - 270° (sintring ved 267°).' 10.0 g of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride is added to 100 ml of ethanol and heated with 4 g of solid sodium hydroxide and 12 g of ethyl bromide for 3 hours at a bath temperature of 100° under reflux. After evaporation in a vacuum, this is shaken out with methylene chloride and 3-n caustic soda and dried over Na 2 SO 4 . Ethanol-containing hydrochloric acid is added to the base obtained by evaporation, and after crystallization and recrystallization in methanol, 9.5 g of colorless rac-4-(3,4-dichloro-phenyl)-2-ethyl-1,2,3,4-tetrahydro is obtained -7-Methoxyisoquinoline hydrochloride with m.p. 269 - 270° (sintering at 267°).'
EKSEMPEL 24 EXAMPLE 24
Av 4,50 g rac-4-(3,4-diklorfenyl)-2-etyl-l,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid isoleres den frie basen ved utrystning med kloroform og mettet natriumbikarbonatlosning. Efter tilsetning av lOO ml 48%'ig bromhydrogensyre, hvorved hydrobromid umiddelbart dannes som bunnfall, oppvarmes losningen 4 timer under omroring ved en badtemperatur på 160° og under tilbakelop. Det rystes ut med 500 ml kloroform og 300 ml mettet natriumbikarbonatlosning, hvorefter det torkes med Na^SO^ og inndampes i vakuum. Efter surgjoring med etanolholdig saltsyre, krystallisasjon med etanol-eter og omkrystallisasjon i metanol erholder man 3,0 g fargelost rac-4-(3,4-diklorfenyl)-2-etyl-l,2,3,4-tetrahydro-7-isokinolinol-hydroklorid med smp. From 4.50 g of rac-4-(3,4-dichlorophenyl)-2-ethyl-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride, the free base is isolated by shaking with chloroform and saturated sodium bicarbonate solution. After adding 100 ml of 48% hydrobromic acid, whereby hydrobromide is immediately formed as a precipitate, the solution is heated for 4 hours with stirring at a bath temperature of 160° and under reflux. It is shaken out with 500 ml of chloroform and 300 ml of saturated sodium bicarbonate solution, after which it is dried with Na^SO^ and evaporated in vacuo. After acidification with ethanolic hydrochloric acid, crystallization with ethanol-ether and recrystallization in methanol, 3.0 g of colorless rac-4-(3,4-dichlorophenyl)-2-ethyl-1,2,3,4-tetrahydro-7- isoquinolinol hydrochloride with m.p.
-305 - 307°, (sintring ved 260°). -305 - 307°, (sintering at 260°).
EKSEMPEL 25 EXAMPLE 25
Av 500 mg rac^4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid isoleres den frie basen ved hjelp av utrystning mellom kloroform og mettet natriumbikarbonatlosning. From 500 mg of rac^4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride, the free base is isolated by shaking between chloroform and saturated sodium bicarbonate solution.
I en autoklav oppvarmes dette sammen med 5 ml isopropylbromid og 200 mg finrevet soda 3 timer ved 150°. Efter inndampning, utrystning mellom kloroform og 3-n natronlut, tbrking, surgjoring med etanolholdig saltsyre og krystallisasjon og omkrystallisasjon i etanol erholder man 300 mg fargelos rac-4-(3,4-diklorfenyl)-2-isopropyl-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid In an autoclave, this is heated together with 5 ml of isopropyl bromide and 200 mg of finely grated soda for 3 hours at 150°. After evaporation, shaking between chloroform and 3-n sodium hydroxide solution, drying, acidification with ethanolic hydrochloric acid and crystallization and recrystallization in ethanol, 300 mg of colorless rac-4-(3,4-dichlorophenyl)-2-isopropyl-1,2,3 ,4-tetrahydro-7-methoxyisoquinoline hydrochloride
med smp. 245 - 246°. with m.p. 245 - 246°.
EKSEMPEL 26 EXAMPLE 26
Under nitrogen blir 500 mg rac-4-(3,4-diklorfenyl)-2-isopropyl-1,2,3,4-tetrahydro-7-metoksyisokinolin-hydroklorid ioppvarmet 1-IO ml 48%'ig bromhydrogensyre 2 timer ved en badtemperatur på 160° og under tilbakelop. Reaksjonsblandingen inndampes der- Under nitrogen, 500 mg of rac-4-(3,4-dichlorophenyl)-2-isopropyl-1,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride are heated in 1-10 ml of 48% hydrobromic acid for 2 hours at a bath temperature of 160° and under reflux. The reaction mixture is evaporated there-
efter i vakuum, utrystes med kloroform og sodalosning og inndampes. Efter krystallisasjon med petroleter og omkrystal- after in vacuum, shake out with chloroform and soda solution and evaporate. After crystallization with petroleum ether and recrystallization
lisasjon i eter-petroleter erholder man 300 mg fargelost rac-4-(3,4-diklorfenyl)-2-isopropyl-l,2,3,4-tetrahydro-7-isokinolinol med smp. 155 - 156°. lysis in ether-petroleum ether yields 300 mg of colorless rac-4-(3,4-dichlorophenyl)-2-isopropyl-1,2,3,4-tetrahydro-7-isoquinolinol with m.p. 155 - 156°.
Efter surgjoring med etanolholdig saltsyre, krystallisasjon After acidification with ethanolic hydrochloric acid, crystallization
og omkrystallisasjon i etanol-eter erholder man det fargelose hydrokloridet med smp. 274 - 277° (spaltning). and recrystallization in ethanol-ether yields the colorless hydrochloride with m.p. 274 - 277° (decomposition).
EKSEMPEL 27 EXAMPLE 27
500 mg rac-4- (3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid rystes i 20 ml etanol med 200 mg fast natriumhydroksyd og 5 ml benzylbromid 45 minutter ved rom- 500 mg of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride are shaken in 20 ml of ethanol with 200 mg of solid sodium hydroxide and 5 ml of benzyl bromide for 45 minutes at room temperature.
temperatur. Efter inndampning i vakuum, utrysting med kloroform og 3-n natronlut, torking og inndampning og surgjoring med etanolholdig klorhydrogen erholder man i kloroformr-eter •'fargelose krystaller. Omkrystallisasjon i etanol gir 300 mg rac-2- benzyl-4-(3,4-diklorfenyl)-i,2,3,4-tetrahydro-7-metoksyiso-kinolin-hydroklorid med smp. 26.3 - 264° (sintring ved 245°). temperature. After evaporation in vacuum, shaking out with chloroform and 3-n caustic soda, drying and evaporation and acidification with ethanol-containing hydrogen chloride, colorless crystals are obtained in chloroform ether. Recrystallization in ethanol gives 300 mg of rac-2-benzyl-4-(3,4-dichlorophenyl)-i,2,3,4-tetrahydro-7-methoxyisoquinoline hydrochloride with m.p. 26.3 - 264° (sintering at 245°).
EKSEMPEL 28 EXAMPLE 28
Basen som er satt fri ved utrystning med kloroform og 3 N natriumhydroksyd fra 25o mg (o,733 mmol) rac-4-(p-aminofenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolindihydroklorid blandes med 3o ml metanol og 2 ml 35%'ig formalinopplosning. The base liberated by shaking with chloroform and 3 N sodium hydroxide from 250 mg (0.733 mmol) rac-4-(p-aminophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline dihydrochloride is mixed with 30 ml methanol and 2 ml 35% formalin solution.
Etter 1 times henstand ved romtemperatur hydreres 1 time After standing for 1 hour at room temperature, hydrate for 1 hour
med ca. 1 g Raney-nikkel. Etter filtrering gjennom diatomée- with approx. 1 g Raney nickel. After filtration through diatomaceous
jord, inndampning, utrystning mellom kloroform og 3N natriumhydroksyd og inndampning blandes med eter og en liten mengde uopploslig forurensninger fjernes ved filtrering. Etter sur- soil, evaporation, shaking between chloroform and 3N sodium hydroxide and evaporation is mixed with ether and a small amount of insoluble impurities is removed by filtration. After sur-
gjoring med etanolisk saltsyre, inndampning med benzen, krystallisasjon og omkrystallisasjon fra etanol-eter erholder man det fargelose dihydrokloridet av rac-4-/4-(dimetylamino)fenyl7-l, 2, 3, 4-tetrahydro-7-metoksy-2-metylisokinolin med smp. 259 - 26o°C. reaction with ethanolic hydrochloric acid, evaporation with benzene, crystallization and recrystallization from ethanol-ether yields the colorless dihydrochloride of rac-4-/4-(dimethylamino)phenyl7-1,2,3,4-tetrahydro-7-methoxy-2- methylisoquinoline with m.p. 259 - 26o°C.
EKSEMPEL 29 EXAMPLE 29
Til en opplosning av 5,6 g rac-4-/4-(dimetylamino)fenyl/- 1,2,3,4-tetrahydro-4-hydroksy-7-metoksy~2-metyl-isokinolin, To a solution of 5.6 g of rac-4-[4-(dimethylamino)phenyl]-1,2,3,4-tetrahydro-4-hydroxy-7-methoxy~2-methyl-isoquinoline,
som ble satt fritt fra hydrokloridet, i iseddik tilfores o,8 g lo% Pd-C og opplosningen hydreres 15 timer ved 6o°C og 3,5 atm. Etter frafiltrering av katalysatoren inndampes i vakuum, rystes ut mellom etylenklorid og natronlut;- inndampes, surgjores med etanolisk saltsyre og krystalliseres fra etanol-eter. Man får fargelost dihydroklorid av rac-4-/4-(dimetylamino)feny17-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med smp. which was set free from the hydrochloride, in glacial acetic acid add o.8 g lo% Pd-C and the solution is hydrated for 15 hours at 6o°C and 3.5 atm. After filtering off the catalyst, evaporate in vacuum, shake out between ethylene chloride and caustic soda; - evaporate, acidify with ethanolic hydrochloric acid and crystallize from ethanol-ether. Colorless dihydrochloride of rac-4-(dimethylamino)phenyl 17-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline is obtained with m.p.
259 - 26o°C. 259 - 26o°C.
EKSEMPEL 3o EXAMPLE 3o
Man reduserer rac-4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metyl-isokinolin-3-on-hydroklorid i tetrahydrofuran med litiumaluminiumhydrid og får etter vanlig opp-arbeiding 4-(4-klorfenyl)-1,2,3,4-tetrahydro-6,7-dimetoksy-2-metylisokinolin-hydroklord med smp. 19o - 22o°C. Den fri basen krystalliserer fra eter-petroleter med smp. lol-lo2°C. One reduces rac-4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-isoquinolin-3-one hydrochloride in tetrahydrofuran with lithium aluminum hydride and, after usual work-up, obtain 4-(4-chlorophenyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methylisoquinoline hydrochloride with m.p. 19o - 22o°C. The free base crystallizes from ether-petroleum ether with m.p. lol-lo2°C.
EKSEMPEL 31 EXAMPLE 31
lo,76 g (3o mmol) rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin-hydroklorid overfores ved utrysting mellom 2N sodalosning og kloroform i den oljeaktige frie basen og blandes med en losning av 11,6o g (3o mmol) (-)-2,3-di-0-p toluyl (RR) vinsyre (M = 386,36) i 3oo ml metanol. Den klare losningen podes med noe 2,3-di-0-p-toluyl-(R,R)-tartrat av (-)-(R)-4-(3,4-diklorfenyl)-l,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin og får stå ved romtemperatur til en stor mengde av dette saltet har dannet seg. Losningen må eventuelt inndampes litt i vakuum. Etter filtreringen erholder man 2,3-di-0-p-toluyl-(R,R)-tartratet av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokiriolin hvis renhet proves ved utrysting av saltet mellom 2N sodalosning og kloroform, surgjoring av den fri base med etanolisk saltsyre og krystallisasjon av hydrokloridet fra metanol-eter. 2,3-di-O-p-toluyl-(R,R)-tartratet av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolinet må eventuelt omkrystalliseres fra metanol til dets hydroklorid viser den onskede dreining. 10.76 g (30 mmol) of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline hydrochloride are transferred by shaking between 2N soda solution and chloroform in the oily free base and mixed with a solution of 11.60 g (30 mmol) (-)-2,3-di-0-p toluyl (RR) tartaric acid (M = 386.36) in 300 ml of methanol. The clear solution is seeded with some 2,3-di-O-p-toluyl-(R,R)-tartrate of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3, 4-tetrahydro-7-methoxy-2-methylisoquinoline and allowed to stand at room temperature until a large amount of this salt has formed. The solution may have to be slightly evaporated in a vacuum. After filtration, the 2,3-di-0-p-toluyl-(R,R)-tartrate of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-7-methoxy-2-methylisokiriolin whose purity is tested by shaking out the salt between 2N soda solution and chloroform, acidifying the free base with ethanolic hydrochloric acid and crystallization of the hydrochloride from methanol-ether. The 2,3-di-O-p-toluyl-(R,R)-tartrate of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy- The 2-methylisoquinoline may have to be recrystallized from methanol until its hydrochloride shows the desired rotation.
Det rene 2,3-di-O-p-toluyl-(R,R)-tartratet av (-) - (R)-4-(3, 4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolinet viser smeltepunktet 188 - 189° fra metanol. The pure 2,3-di-O-p-toluyl-(R,R)-tartrate of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7- the methoxy-2-methylisoquinoline shows a melting point of 188 - 189° from methanol.
Hydrokloridet av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin viser smeltepunkt 24o - 242° fra metanol-eter. The hydrochloride of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline shows a melting point of 24° - 242° from methanol-ether.
Ved utrysting av hydrokloridet av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med 2N sodalosning og kloroform erholder man den oljeaktige fri basen (_)_(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin. By shaking off the hydrochloride of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline with 2N soda solution and chloroform, the oily free the base (_)_(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline.
De metanoliske moderlutene av (-)-(R)-4-(3,4-diklorfenyl)-1, 2, 3,4-tetrahydro-7-metoksy-2-metylisokinolin inndampes til det på nytt har dannet seg en stor mengde krystaller. Etter omkrystallisasjon fra metanol erholder man 2,3-di-O-p-toluyl-(R,R)-tartratet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3, 4-tetrahydro-7-metoksy-2-metylisokinolin med smeltepunktet 186 - 187°. Dets optiske renhet proves igjen ved overforingen i hydrokloridet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin og bestemmelsen av dreiningen til hydrokloridet. The methanolic mother liquors of (-)-(R)-4-(3,4-dichlorophenyl)-1, 2, 3,4-tetrahydro-7-methoxy-2-methylisoquinoline are evaporated until a large amount of crystals. After recrystallization from methanol, the 2,3-di-O-p-toluyl-(R,R)-tartrate of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3, 4- tetrahydro-7-methoxy-2-methylisoquinoline with a melting point of 186 - 187°. Its optical purity is again proved by the conversion into the hydrochloride of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline and the determination of the rotation of the hydrochloride.
2,3-di-O-p-toluyl-(R,R)-tartrat av (+)-(S)-4-(3,4-diklorfenyl)-1, 2, 3, 4-tetrahydro-7-metoksy-2-metylisokinolin; Z~ 3<i7>^~ -7o°. 2,3-di-O-p-toluyl-(R,R)-tartrate of (+)-(S)-4-(3,4-dichlorophenyl)-1, 2, 3, 4-tetrahydro-7-methoxy- 2-methylisoquinoline; Z~ 3<i7>^~ -7o°.
Ved utrysting av basen av 2,3-di-O-p-toluyl-(R,R)-tartratet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med 2N sodalosning og kloroform, surgjoring med etanolisk saltsyre og krystallisasjon fra metanol-eter erholder man hydrokloridet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med smeltepunkt 24o - 242°. By shaking out the base of the 2,3-di-O-p-toluyl-(R,R)-tartrate of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro -7-methoxy-2-methylisoquinoline with 2N sodium hydroxide solution and chloroform, acidification with ethanolic hydrochloric acid and crystallization from methanol-ether yields the hydrochloride of (+)-(S)-4-(3,4-dichlorophenyl)-1,2, 3,4-tetrahydro-7-methoxy-2-methylisoquinoline with melting point 24o - 242°.
Hydrokloridet lar seg også isolere direkte når de metanoliske moderlutene av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisbkinolin utrystes med.2N sodalosning og . kloroform og surgjores med etanolisk saltsyre. Etter atskillelse av en liten mengde rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyl-isokinolin-hydroklorid og omkrystallisasjon av moderluten lar seg likeledes rent (+)-(S)-4-(3,4-diklor-fenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin erholde. The hydrochloride can also be isolated directly when the methanolic mother liquors of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisbquinoline are shaken with 2N soda ash and . chloroform and acidified with ethanolic hydrochloric acid. After separation of a small amount of rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-isoquinoline hydrochloride and recrystallization of the mother liquor, pure (+) -(S)-4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline are obtained.
Hydroklorid av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin: Hydrochloride of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline:
Ved utrysting av hydrokloridet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med 2N sodalosning og kloroform erholder man den oljeaktige fri basen 4-(3, 4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin: By shaking out the hydrochloride of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline with 2N soda solution and chloroform, the oily free the base 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline:
Hydrokloridet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin kan videre også utvinnes fra 2,3-di-0-benzyl-(S,S)-tartratet av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin: Den fra de metanoliske moderluter av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin som ovenfor beskrevne frigjorte base krystalliseres med en ekvivalent (+)-2,3-di-0-benzyl-(S,S)-vinsyre fra metanol-eter og man erholder 2,3-di-O-benzyl-(S,S)-tartrat av (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin med smeltepunktet 157 - 158°. The hydrochloride of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline can furthermore also be recovered from 2,3-di-0- The benzyl-(S,S)-tartrate of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline: That from the methanolic mother liquors of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline as above-described liberated base are crystallized with an equivalent of (+)- 2,3-di-O-benzyl-(S,S)-tartaric acid from methanol-ether and 2,3-di-O-benzyl-(S,S)-tartrate is obtained from (+)-(S)- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2-methylisoquinoline with melting point 157 - 158°.
Renheten blir igjen kontrollert ved dreiningen av det frem- The cleanliness is again checked by turning the forward
stilte hydrokloridet fra 2,3-di-0-benzyl-(S,S)-tartratet av (+)_(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolinet. prepared the hydrochloride from the 2,3-di-O-benzyl-(S,S)-tartrate of (+)_(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7 -methoxy-2-methylisoquinoline.
2,3-di-0-benzyl-(S;S)-tartrat av (+)-(S)-4-(3,4-diklbrfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metylisokinolin: 2,3-di-O-benzyl-(S;S)-tartrate of (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy- 2-methylisoquinoline:
EKSEMPEL 32 EXAMPLE 32
Ved utrysting av de inndampede moderluter av 2,3-di-O-p-toluyl-(RR)-tartratet av (-)-(R)-4-(3,4-diklorfenyl)-1,2,3,4- . tetrahydro-7-metoksyisokinolin med 2N sodalosning og kloroform erholdes ca. 12 g (ca. 39 mmol) av en blanding av de oljeaktige frie basene rac-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-isokinolin-hydroklorid og (+)-(S)-4-(3,4-diklorfenyl)-1,2,3, 4-tetrahydro-7-metoksyisokinolin. Det blir opplost i 2oo ml metanol, blandet med lo ml (126 mmol) 35%'ig formaldehydlosning (Merck) og rystet 2 timer til det harpiksaktige bunnfallet praktisk talt har lost seg igjen. Etter tilsats av 5 g Raney-nikkel hydreres ca. 1 time under rysting ved romtemperatur, filtreres gjennom diatomerjord, surgjores med etanolisk saltsyre og inndampes i vakuum. Fra etanol-eter krystalliserer forst 4,2 g av en blanding med smeltepunktet 245°, som ifolge dreiningen hovedsakelig består av racemisk 4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksy-2-metyliso-kinolin. De folgende krystallisater gir tilsammen 6,4 g (17,8 mmol) (+)-(S)-4-(3,4-diklorfenyl)-1,2,3,4-tetrahydro-7-metoksyisokinolin med smeltepunktet 24o - 242 o og / — a7D 25 <= >+8,2°, f* 72s\ e +lo,4° og Z"a7436 +14, o°. By shaking off the evaporated mother liquors of the 2,3-di-O-p-toluyl-(RR)-tartrate of (-)-(R)-4-(3,4-dichlorophenyl)-1,2,3,4- . tetrahydro-7-methoxyisoquinoline with 2N soda solution and chloroform is obtained approx. 12 g (approx. 39 mmol) of a mixture of the oily free bases rac-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-isoquinoline hydrochloride and (+)- (S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline. It is dissolved in 2oo ml of methanol, mixed with 10 ml (126 mmol) of 35% formaldehyde solution (Merck) and shaken for 2 hours until the resinous precipitate has practically dissolved again. After adding 5 g of Raney nickel, approx. 1 hour under shaking at room temperature, filtered through diatomaceous earth, acidified with ethanolic hydrochloric acid and evaporated in vacuum. 4.2 g of a mixture with a melting point of 245° crystallizes from ethanol-ether, which, according to the rotation, mainly consists of racemic 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxy-2 -methylisoquinoline. The following crystallisates give a total of 6.4 g (17.8 mmol) (+)-(S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-7-methoxyisoquinoline with a melting point of 24o - 242 o and / — a7D 25 <= >+8.2°, f* 72s\ e +lo.4° and Z"a7436 +14, o°.
Claims (6)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO740554A NO135062C (en) | 1970-01-06 | 1974-02-19 | |
NO740555A NO740555L (en) | 1970-01-06 | 1974-02-19 | Isoquinoline derivatives for use as intermediates for the preparation of 2-alkyl- or 2-phenyl-lower alkyl-1,2,3,4-tetrahydro-4-isoquinoline derivatives. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH10370A CH527194A (en) | 1970-01-06 | 1970-01-06 | Process for the preparation of isoquinoline derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
NO135315B true NO135315B (en) | 1976-12-13 |
NO135315C NO135315C (en) | 1977-03-23 |
Family
ID=4179328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO7121A NO135315C (en) | 1970-01-06 | 1971-01-05 |
Country Status (19)
Country | Link |
---|---|
JP (1) | JPS5515476B1 (en) |
AT (1) | AT303041B (en) |
BE (1) | BE761219A (en) |
CA (1) | CA999866A (en) |
CH (2) | CH538477A (en) |
DE (1) | DE2062001C2 (en) |
DK (1) | DK125021B (en) |
ES (1) | ES387016A1 (en) |
FI (1) | FI49503C (en) |
FR (1) | FR2081412B1 (en) |
GB (1) | GB1335261A (en) |
IE (1) | IE34859B1 (en) |
IL (1) | IL35916A (en) |
NL (1) | NL171444C (en) |
NO (1) | NO135315C (en) |
PH (1) | PH9682A (en) |
SE (3) | SE386672B (en) |
YU (1) | YU33660B (en) |
ZA (1) | ZA708590B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4719216A (en) * | 1983-06-23 | 1988-01-12 | Mcneilab, Inc. | Hexahydropyrrolo(2,1-A)isoquinoline derivatives as antidepressants |
ZA844402B (en) * | 1983-06-23 | 1986-01-29 | Mcneil Pharmaceutical | Hexahydropyrrolo(2,1-a)isoquinoline derivatives |
US4595688A (en) * | 1983-06-23 | 1986-06-17 | Mcneilab, Inc. | Hexahydropyrrolo[2,1-a]isoquinoline derivatives and antidepressant use thereof |
GB2271566A (en) * | 1992-10-14 | 1994-04-20 | Merck & Co Inc | HIV integrase inhibitors |
AU781179B2 (en) | 1999-11-03 | 2005-05-12 | Albany Molecular Research, Inc. | Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US7163949B1 (en) * | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
RU2293728C2 (en) * | 1999-11-03 | 2007-02-20 | Эймр Текнолоджи, Инк. | Derivatives of tetrahydroisoquinoline, pharmaceutical composition containing thereof, method for inhibition of synaptic uptake of dopamine and treatment method |
EP1113007A1 (en) | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisoquinoline compounds as estrogen agonists/antagonists |
MXPA03000275A (en) | 2000-07-11 | 2004-12-13 | Albany Molecular Res Inc | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof. |
MX2007000428A (en) | 2004-07-15 | 2008-03-05 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin. |
JP2008543880A (en) | 2005-06-17 | 2008-12-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Naphthyridine compounds |
UA95454C2 (en) | 2005-07-15 | 2011-08-10 | Амр Текнолоджи, Інк. | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
AR071997A1 (en) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
KR20120023072A (en) | 2009-05-12 | 2012-03-12 | 브리스톨-마이어스 스큅 컴퍼니 | Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
MX2011011907A (en) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4- tetrahydroisoquinoline and use thereof. |
MX2011011901A (en) | 2009-05-12 | 2012-01-20 | Albany Molecular Res Inc | Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1670694B2 (en) * | 1966-05-05 | 1976-07-22 | Hoechst Ag, 6000 Frankfurt | METHOD FOR MANUFACTURING TETRAHYDROISOCHINOLINES |
-
1970
- 1970-01-06 CH CH1011872A patent/CH538477A/en not_active IP Right Cessation
- 1970-01-06 CH CH10370A patent/CH527194A/en not_active IP Right Cessation
- 1970-12-16 SE SE7313623A patent/SE386672B/en unknown
- 1970-12-16 DE DE2062001A patent/DE2062001C2/en not_active Expired
- 1970-12-16 SE SE17063/70A patent/SE368401B/xx unknown
- 1970-12-21 ZA ZA708590A patent/ZA708590B/en unknown
- 1970-12-28 IL IL35916A patent/IL35916A/en unknown
- 1970-12-29 NL NLAANVRAGE7018956,A patent/NL171444C/en not_active IP Right Cessation
- 1970-12-31 FI FI703519A patent/FI49503C/en active
-
1971
- 1971-01-04 IE IE6/71A patent/IE34859B1/en unknown
- 1971-01-05 AT AT4571A patent/AT303041B/en not_active IP Right Cessation
- 1971-01-05 ES ES387016A patent/ES387016A1/en not_active Expired
- 1971-01-05 FR FR7100097A patent/FR2081412B1/fr not_active Expired
- 1971-01-05 DK DK2571AA patent/DK125021B/en not_active IP Right Cessation
- 1971-01-05 GB GB45471A patent/GB1335261A/en not_active Expired
- 1971-01-05 BE BE761219A patent/BE761219A/en not_active IP Right Cessation
- 1971-01-05 NO NO7121A patent/NO135315C/no unknown
- 1971-01-06 YU YU19/71A patent/YU33660B/en unknown
- 1971-01-06 JP JP7194A patent/JPS5515476B1/ja active Pending
- 1971-01-06 CA CA102,060A patent/CA999866A/en not_active Expired
- 1971-01-07 PH PH12087*UA patent/PH9682A/en unknown
-
1973
- 1973-10-05 SE SE7313622A patent/SE399879B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE2062001A1 (en) | 1971-07-15 |
FI49503C (en) | 1975-07-10 |
NO135315C (en) | 1977-03-23 |
SE368401B (en) | 1974-07-01 |
IL35916A0 (en) | 1971-02-25 |
SE399879B (en) | 1978-03-06 |
GB1335261A (en) | 1973-10-24 |
JPS5515476B1 (en) | 1980-04-23 |
YU33660B (en) | 1977-12-31 |
CA999866A (en) | 1976-11-16 |
NL171444C (en) | 1983-04-05 |
IE34859B1 (en) | 1975-09-03 |
FR2081412B1 (en) | 1974-04-12 |
NL7018956A (en) | 1971-07-08 |
IL35916A (en) | 1973-11-28 |
IE34859L (en) | 1971-07-06 |
PH9682A (en) | 1976-02-10 |
AT303041B (en) | 1972-11-10 |
ZA708590B (en) | 1971-09-29 |
CH527194A (en) | 1972-08-31 |
NL171444B (en) | 1982-11-01 |
YU1971A (en) | 1977-06-30 |
DK125021B (en) | 1972-12-18 |
CH538477A (en) | 1973-06-30 |
FI49503B (en) | 1975-04-01 |
FR2081412A1 (en) | 1971-12-03 |
BE761219A (en) | 1971-07-05 |
ES387016A1 (en) | 1976-05-01 |
DE2062001C2 (en) | 1986-10-16 |
SE386672B (en) | 1976-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO135315B (en) | ||
US4259338A (en) | Benzofuranyl-tetrahydropyridines and -piperidines, their acid addition salts and antidepressant preparations thereof | |
US3433791A (en) | Endoethano nor oripavines and nor thebaines | |
JPS6350354B2 (en) | ||
US3947456A (en) | Substituted 4-phenyl isoquinolines | |
IE46087B1 (en) | Trisubstituted 1-phenyl-2,3,4,5 - tetra-hydro-1h-3-benzazepine compounds | |
NO163552B (en) | COMPOSITE SUBJECT. | |
Manske | THE ALKALOIDS OF FUMARIACEOUS PLANTS: XVIII. FUMARIA OFFICINALIS L. | |
Augstein et al. | Adrenergic neurone blocking agents derived from 1, 4-benzodioxan | |
US3592824A (en) | 3-substituted amino-1,2,3,4-tetrahydrocarbazoles | |
US3717641A (en) | Derivatives of dibenzo cycloocten-5,11-imine | |
US3574232A (en) | 3-aminoalkyl-1-phenyl-indolines | |
Small et al. | The catalytic hydrogenation of the halogenomorphides: Dihydrodesoxymorphine-D1 | |
US3466288A (en) | 9,4alpha-iminoethanoanthracenes and indeno(2,1-j)isoquinolines | |
US3238212A (en) | 1-substituted-1-phenyl(or substituted phenyl)-2-[2-methyl-6, 7-substituted-1, 2, 3, 4-tetrahydroisoquinolinyl-(1)] ethanes | |
Mooradian et al. | 3-Aminotetrahydrocarbazoles as a new series of central nervous system agents | |
GB2056435A (en) | Novel Tetrahydropyridine and Piperidine Substituted Benzofuranes and Related Compounds | |
Lewis et al. | Novel analgesics and molecular rearrangements in the morphine-thebaine group. 28. Derivatives of 6, 14-endo-etheno-7-Oxo-6, 7, 8, 14-tetrahydrothebaine and 6, 14-endo-etheno-6, 7, 8, 14-tetrahydrothebaine | |
EP0178201A1 (en) | Furo[3,2-c]pyridine derivatives, their preparation and their therapeutical use | |
Weiss et al. | Derivatives of Morphine. IV. 1 14-Hydroxymorphine and 14-Hydroxydihydromorphine | |
US3347870A (en) | Aryl-tetralyl compounds and a process for their production | |
NO800725L (en) | POLICE SUBSTITUTED DIAZATRICYCLES. | |
NO751009L (en) | ||
US3952017A (en) | Tricyclic compounds | |
US4136116A (en) | Tricyclic compounds |